{"status":"success","data":[["Unnamed: 0","person_id","birthdate","weight","height","Blood Pressure","Age at Reporting","gender","Diagnosis_Date","Date enrolled in HIV","ART Start Date","CD4_Count","Current Regimen Line","Current_WHO_HIV_Stage","Viral_Load","TPT Start Date","TPT Outcome","Establishment","Date Scheduled","Next_clinical_appointment","NCDs","Encounter_Date","days_late","iit_flag","early_arrival","on_time","late_arrival","past_encounters","pct_late_arrivals","prev_iit_status","second_last_iit_status","num_past_iits","success_flag","overall_appointment_success","time_since_diagnosis_at_scheduled_appointment","age_at_encounter","age_group","Is_ART","risk_tier","predicted_iit_prob","adherence_predicted","adherence_actual","query_1","model_response_1","query_2","model_response_2","query_3","model_response_3","shap_explanation","Baseline CD4 result","Last WHO Stage Date","Last VL Validity","Last VL Justification","Last VL Date","Active in TB","TPT Outcome Date","Months Of Prescription","num__num_past_iits","num__CD4_Count","num__Viral_Load","num__height","num__weight","num__overall_appointment_success","num__time_since_diagnosis_at_scheduled_appointment","num__prev_iit_status","num__second_last_iit_status","cat__Current_WHO_HIV_Stage_1","cat__Current_WHO_HIV_Stage_2","cat__Current_WHO_HIV_Stage_3","cat__Current_WHO_HIV_Stage_4","cat__Current_WHO_HIV_Stage_unknown","cat__gender_F","cat__gender_M","cat__age_group_18-30","cat__age_group_31-45","cat__age_group_46-60","cat__age_group_61+","cat__age_group_<18","cat__age_group_unknown","cat__risk_tier_High","cat__risk_tier_Low","cat__risk_tier_Medium","cat__Is_ART_0.0","cat__Is_ART_1.0","base_value","shap_value_space","calc_prob_from_shap","prob_delta_check","top1_feature","top2_feature","top3_feature","top1_shap","top2_shap","top3_shap","top1_direction","top2_direction","top3_direction","proba_without_top1","proba_without_top2","proba_without_top3","top1_global_rank","top2_global_rank","top3_global_rank","strong_factor_count"],["0","1544003664","7\/19\/1992","70","165","129\/88","32","M","06\/12\/2018","06\/12\/2019","06\/12\/2019","603","First line","1","0","11\/04\/2019","Treatment completed","Established","22\/04\/2025","7\/26\/2025","","4\/19\/2025","-3","0","1","0","0","3","0","0","0","0","1","100","2506","32.75838467","31-45","1","Low","0.520046391","1","on time","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The Patient is virally suppressed, WHO1; continue first-line ART, routine VL\/renal monitoring, address borderline BP\/BMI with lifestyle counseling, and reinforce adherence given elevated IIT prediction.","What should be considered for ART treatment when no NCDs are recorded for this patient?","The Patient has no recorded NCDs; continue first-line DTG-based ART, and routinely screen for hypertension\/diabetes, renal function, lipids, weight, and potential drug interactions.","What factors suggest a need to adjust the patient\u2019s ART regimen?","The Patient is stable with suppressed VL; continue current first-line, consider 6-month dispensing, and maintain routine NCD screening\u2014BP, glucose, renal\u2014diastolic is borderline.","The model predicted follow-up mainly because long time since diagnosis ~6.9 years, CD4 count 603, and being on ART increase risk. In our cohort, this profile often appeared before missed or late appointments.","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""],["1","1666700035","01\/01\/1967","74","163","136\/72","58","F","3\/18\/2007","3\/18\/2008","12\/16\/2008","156","First line","1","0","10\/27\/2016","Treatment completed","Established","27\/05\/2025","8\/23\/2025","Hypertension","5\/23\/2025","-4","0","1","0","0","3","50","0","0","0","1","50","6645","58.40109514","46-60","1","High","0.322298911","0","on time","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The Patient is virologically suppressed; continue first-line. CD4 156\u2014maintain cotrimoxazole and monitor OIs. Optimize hypertension control, check renal function (if on TDF), enhance adherence support.","The patient has both HIV and Hypertension. How might this affect ART treatment or what considerations are important in managing this patient?","The Patient has hypertension; I'd favor INSTI ART, review antihypertensive\u2013ART interactions, avoid boosted PIs, monitor renal function\/potassium\/lipids, optimize BP\/cardiovascular risk, and simplify regimens for adherence.","What factors suggest a need to adjust the patient\u2019s ART regimen?","The Patient would continue standard first-line ART; absence of recorded NCDs doesn\u2019t change regimen; still screen regularly for NCDs and interactions at each visit.","The model predicted no action with mixed signals: long time since diagnosis ~18.2 years and weight 74 kg increase risk, while overall appointment success ~50% decrease risk. In our cohort, this balance aligned with a lower-risk decision.","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""],["2","1666700461","01\/01\/1985","58","154","120\/84","40","F","12\/29\/2009","10\/04\/2010","10\/04\/2010","406","First line","1","0","02\/06\/2016","Treatment completed","Established","26\/04\/2025","7\/26\/2025","","4\/26\/2025","0","0","0","1","0","3","0","0","0","0","1","100","5597","40.31485284","31-45","1","Low","0.398082583","0","on time","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The Patient remains stable and suppressed; continue first-line ART, plan annual VL around June\u2013July 2025, consider 6\u2011month dispensing, reinforce adherence, and maintain routine NCD\/cervical screening.","What should be considered for ART treatment when no NCDs are recorded for this patient?","The Patient has no recorded NCDs; continue current first-line ART, maintain VL\/CD4 monitoring, and keep periodic NCD screening and drug interaction review at each visit.","What factors suggest a need to adjust the patient\u2019s ART regimen?","The Patient can continue current first-line ART with routine viral load and safety labs; no NCD interactions, but continue periodic NCD screening and risk management.","The model predicted no action mainly because long time since diagnosis ~15.3 years, CD4 count 406, and being on ART increase risk. In our cohort, this profile often appeared before missed or late appointments.","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""],["3","1666700956","6\/15\/1953","63.5","166","155\/85","72","M","10\/28\/2010","10\/28\/2010","3\/31\/2012","300","First line","1","0","08\/08\/2019","Treatment completed","Established","23\/06\/2025","8\/28\/2025","","6\/23\/2025","0","0","0","1","0","3","25","0","0","0","1","75","5352","72.02190281","61","1","Medium","0.360270971","0","on time","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The Patient remains virologically suppressed; let's continue ART, tackle hypertension and cardiovascular risk, and bolster adherence\/retention with routine monitoring given age and CD4 300.","What should be considered for ART treatment when no NCDs are recorded for this patient?","The Patient lacks documented NCDs; maintain current suppressive ART, but re-screen\u2014BP 155\/85 suggests hypertension\u2014optimize cardiovascular risk and monitor renal\/bone health given age.","What factors suggest a need to adjust the patient\u2019s ART regimen?","The Patient has no recorded NCDs; continue first-line ART given suppression, but still screen for hypertension, renal\/hepatic disease, cardiovascular risks, drug interactions, and frailty.","The model predicted no action with mixed signals: long time since diagnosis ~14.7 years increase risk, while overall appointment success ~75% and Current WHO HIV Stage 1 decrease risk. In our cohort, this balance aligned with a lower-risk decision.","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""],["4","1666701048","01\/01\/1964","72.5","171","117\/72","61","M","10\/20\/2008","02\/07\/2011","05\/06\/2011","559","First line","1","44","11\/14\/2019","Treatment completed","Established","29\/05\/2025","8\/27\/2025","Diabetes","5\/29\/2025","0","0","0","1","0","3","0","0","0","0","1","100","6065","61.4072553","61","1","Low","0.489938477","0","on time","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The Patient is suppressed and stable; continue regimen, consider 3\u20136\u2011month dispensing, align diabetes therapy\/interaction review, monitor renal-metabolic labs, and maintain VL with cardiovascular risk management.","The patient has both HIV and Diabetes. How might this affect ART treatment or what considerations are important in managing this patient?","The Patient has diabetes, so choose metabolically friendly ART; closely monitor weight, lipids, kidneys and glycemia; watch metformin\u2013dolutegravir interaction (limit dose), avoid boosters, optimize cardioprotection.","What factors suggest a need to adjust the patient\u2019s ART regimen?","The Patient, if without NCDs, can continue current first-line ART, while ensuring routine NCD screening, cardiovascular risk review, adherence support, and age-appropriate preventive care.","The model predicted follow-up mainly because long time since diagnosis ~16.6 years, CD4 count 559, and being on ART increase risk. In our cohort, this profile often appeared before missed or late appointments.","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""],["5","1666701287","10\/30\/1965","79.5","166","114\/74","59","F","08\/09\/2011","08\/09\/2011","09\/12\/2011","300","First line","1","51","7\/18\/2019","Treatment completed","Not Established","16\/04\/2025","7\/27\/2025","Dyslipidemia","4\/16\/2025","0","0","0","1","0","3","25","0","0","0","1","75","4999","59.46064339","46-60","1","Medium","0.426492709","0","on time","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The Patient has low-level viremia (51); let\u2019s reinforce adherence, recheck VL in 3 months, and optimize dyslipidemia\/weight, cardiovascular risk, and statin-ART interactions.","The patient has both HIV and Dyslipidemia. How might this affect ART treatment or what considerations are important in managing this patient?","The Patient is virally suppressed; with dyslipidemia, prefer TDF\/3TC\/DTG, avoid boosted PIs\/abacavir if ASCVD risk, regularly check lipids, and use statins mindful of ART interactions.","What factors suggest a need to adjust the patient\u2019s ART regimen?","The Patient has dyslipidemia recorded; if none were present, standard first-line DTG-based therapy remains appropriate, with routine viral-load monitoring and adherence support.","The model predicted no action with mixed signals: long time since diagnosis ~13.7 years and weight 80 kg increase risk, while overall appointment success ~75% decrease risk. In our cohort, this balance aligned with a lower-risk decision.","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""],["6","1666701702","01\/01\/1968","46","169","137\/92","57","M","01\/08\/2013","01\/08\/2013","1\/26\/2019","608","First line","1","0","12\/02\/2019","Treatment completed","Established","17\/04\/2025","7\/17\/2025","","4\/17\/2025","0","0","0","1","0","3","0","0","0","0","1","100","4482","57.29226557","46-60","1","Low","0.521780563","1","on time","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The Patient is stable and suppressed; continue ART, address underweight and elevated BP, assess cardiovascular risk, check renal\/bone health if on TDF; routine VL.","What should be considered for ART treatment when no NCDs are recorded for this patient?","The Patient seems stable on first-line; continue ART, but screen and manage NCDs: hypertension (137\/92), underweight (BMI ~16), lipids, glucose, renal\/hepatic function, interactions.","What factors suggest a need to adjust the patient\u2019s ART regimen?","The Patient can continue first-line ART; VL suppressed. No NCDs recorded\u2014still screen for hypertension\/diabetes, monitor renal\/liver function, BMI; no regimen changes unless NCDs emerge.","The model predicted follow-up with mixed signals: a very long time since diagnosis ~12.3 years and age 46\u201360 both increase the likelihood of a missed\/late visit in our data, while overall appointment success (100%) decreases it. Taken together, the upward drivers outweighed the protective effect.","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""],["7","1666701934","11\/24\/1979","71","168","127\/81","45","F","2\/14\/2013","2\/14\/2014","7\/18\/2014","231","First line","1","0","9\/29\/2016","Treatment completed","Established","06\/05\/2025","8\/13\/2025","","5\/15\/2025","9","0","0","0","1","3","25","0","0","0","0","75","4464","45.44832307","46-60","1","Medium","0.390561302","0","on time","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The Patient is virologically suppressed; continue ART, reinforce adherence given recent lateness and medium IIT risk, plan VL Feb 2026, consider DSD\/MMD; assess CD4 recovery.","What should be considered for ART treatment when no NCDs are recorded for this patient?","The Patient is stable; with no NCDs, continue current first-line ART, reinforce adherence, consider longer refill if reliable, and maintain routine NCD screening given age.","What factors suggest a need to adjust the patient\u2019s ART regimen?","The Patient has no NCDs; keep her on first-line ART with suppressed VL, maintain routine labs, and continue NCD screening with vigilance for drug interactions.","The model predicted no action with mixed signals: long time since diagnosis ~12.2 years and weight 71 kg increase risk, while overall appointment success ~75% decrease risk. In our cohort, this balance aligned with a lower-risk decision.","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""],["8","1666702184","11\/22\/2014","25","125","123\/78","10","F","2\/15\/2015","2\/20\/2015","2\/20\/2015","794","First line","1","0","2\/20\/2015","Treatment completed","Established","19\/04\/2025","7\/19\/2025","","4\/19\/2025","0","0","0","1","0","3","0","0","0","0","1","100","3716","10.40657084","<18","1","Low","0.568025131","1","on time","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The Patient remains suppressed; continue first-line, adjust dosing with growth, monitor puberty and labs, recheck borderline BP, and maintain adherence with routine viral load.","What should be considered for ART treatment when no NCDs are recorded for this patient?","The Patient has no NCDs\u2014no ART adjustments needed; continue first-line ART with routine VL, weight-band dosing, and ongoing screening for emerging NCDs and metabolic\/growth issues.","What factors suggest a need to adjust the patient\u2019s ART regimen?","The Patient is suppressed and without NCDs; continue current first-line ART with weight-based dosing, monitor toxicity\/growth, maintain NCD screening, and reinforce adherence.","The model predicted follow-up mainly because long time since diagnosis ~10.2 years, CD4 count 794, and age group <18 increase risk. In our cohort, this profile often appeared before missed or late appointments.","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""],["9","1666702391","01\/01\/1970","65","153","101\/75","55","F","1\/18\/2016","1\/18\/2016","9\/15\/2014","311","First line","1","0","08\/06\/2019","Treatment completed","Established","07\/05\/2025","08\/05\/2025","","05\/07\/2025","0","0","0","1","0","3","0","0","0","0","1","100","3397","55.34565366","46-60","1","Low","0.3884932","0","on time","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The Patient is stable and suppressed; continue first-line ART, consider longer MMD, align refills to August visit, and address overweight\/cardiovascular screening and routine VL\/NCD\/cervical surveillance.","What should be considered for ART treatment when no NCDs are recorded for this patient?","The Patient remains virally suppressed; continue first-line ART, with ongoing age-appropriate NCD screening, metabolic\/renal\u2013hepatic monitoring, and routine checks for drug interactions or contraindications.","What factors suggest a need to adjust the patient\u2019s ART regimen?","The Patient can continue current first-line ART; keep routine screening for NCDs\u2014BP, glucose, lipids\u2014plus CVD risk and renal\/hepatic monitoring while VL stays suppressed.","The model predicted no action with mixed signals: long time since diagnosis ~9.3 years and the model counterintuitively thinks overall appointment success ~100% increase risk, while risk tier Low decrease risk. In our cohort, this balance aligned with a lower-risk decision.","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""],["10","1666702684","8\/23\/1990","63","167.5","104\/66","34","F","5\/25\/2017","5\/25\/2017","5\/25\/2017","561","First line","1","0","10\/08\/2019","Treatment completed","Established","23\/01\/2025","7\/23\/2025","","1\/21\/2025","-2","0","0","1","0","3","0","0","0","0","1","100","2800","34.4202601","31-45","1","Low","0.554392282","1","on time","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The Patient looks stable and virologically suppressed; keep her on first\u2011line with 6\u2011month dispensing, plan routine VL Oct\u20112025, screen TB symptoms, reinforce adherence, contraception\/cervical screening.","What should be considered for ART treatment when no NCDs are recorded for this patient?","The Patient is virally suppressed and stable; with no NCDs, continue current first-line ART and six\u2011month dispensing, while screening for NCDs and discussing pregnancy plans.","What factors suggest a need to adjust the patient\u2019s ART regimen?","The Patient is stable on first-line ART; continue regimen with MMD, annual VL, and keep routinely screening for NCDs, interactions, and reproductive health needs.","The model predicted follow-up mainly because long time since diagnosis ~7.7 years, CD4 count 561, and the model counterintuitively thinks overall appointment success ~100% increase risk. In our cohort, this profile often appeared before missed or late appointments.","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""],["11","1666702825","9\/30\/1985","69","162","107\/67","39","F","06\/06\/2018","06\/06\/2018","06\/06\/2018","652","First line","1","0","9\/19\/2018","Treatment completed","Established","24\/05\/2025","8\/28\/2025","","5\/24\/2025","0","0","0","1","0","3","0","0","0","0","1","100","2544","39.64681725","31-45","1","Low","0.548354278","1","on time","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The Patient looks stable on first-line with undetectable VL, CD4 652. Let's continue regimen, reinforce adherence, revisit failure concern, and address overweight and cervical screening.","What should be considered for ART treatment when no NCDs are recorded for this patient?","The Patient should continue current first-line ART; with no NCDs and suppressed VL, keep routine NCD screening and standard lab\/interaction monitoring per guidelines.","What factors suggest a need to adjust the patient\u2019s ART regimen?","The Patient can continue current first-line ART; no NCD contraindications noted. Keep routine monitoring for metabolic\/cardiovascular risks and adherence; consider pregnancy planning and drug-interaction review.","The model predicted follow-up mainly because long time since diagnosis ~7.0 years, CD4 count 652, and the model counterintuitively thinks overall appointment success ~100% increase risk. In our cohort, this profile often appeared before missed or late appointments.","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""],["12","1666702865","09\/12\/1978","57","158","113\/79","46","M","10\/04\/2018","10\/05\/2018","10\/05\/2018","412","First line","1","0","4\/27\/2020","Treatment completed","Established","06\/05\/2025","08\/07\/2025","","05\/06\/2025","0","0","0","1","0","3","0","0","0","0","1","100","2406","46.64750171","46-60","1","Low","0.506394425","1","on time","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The Patient is virally suppressed and stable; I'd continue current regimen, consider 6\u2011month dispensing, annual VL\/renal monitoring (if TDF), and age\u2011appropriate cardiovascular risk screening.","What should be considered for ART treatment when no NCDs are recorded for this patient?","The Patient is virologically suppressed; continue DTG\u2011based first\u2011line ART, use 3\u20136\u2011month refills, and continue routine NCD screening even if none currently documented.","What factors suggest a need to adjust the patient\u2019s ART regimen?","The Patient is stable; continue current first-line ART, maintain routine NCD screening, and reconsider regimen only if comorbidities or drug interactions arise.","The model predicted follow-up mainly because long time since diagnosis ~6.6 years, CD4 count 412, and the model counterintuitively thinks overall appointment success ~100% increase risk. In our cohort, this profile often appeared before missed or late appointments.","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""],["13","1666702879","12\/31\/1976","59","157","112\/80","48","F","11\/21\/2018","12\/27\/2018","12\/27\/2018","516","First line","1","0","12\/10\/2019","Treatment completed","Established","29\/04\/2025","7\/29\/2025","","4\/28\/2025","-1","0","0","1","0","3","0","0","0","0","1","100","2351","48.32580424","46-60","1","Low","0.636943472","1","on time","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The Patient remains stable and undetectable; maintain first-line therapy, annual VL\/renal checks, TB screening, consider 3-6 month refills, reinforce adherence given predicted IIT risk.","What should be considered for ART treatment when no NCDs are recorded for this patient?","The Patient can continue current first\u2011line ART; no NCD contraindications. Continue routine monitoring (renal, BP, glucose), assess pregnancy plans, maintain VL surveillance and adherence support.","What factors suggest a need to adjust the patient\u2019s ART regimen?","The Patient is stable and suppressed; continue first-line ART with 3-month refills, while routinely screening for NCDs, renal\/hepatic function, pregnancy\/contraception, and drug interactions.","The model predicted follow-up mainly because long time since diagnosis ~6.4 years, CD4 count 516, and age group 46-60 increase risk. In our cohort, this profile often appeared before missed or late appointments.","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""],["14","1666703037","6\/15\/1988","75","172","129\/83","37","F","4\/21\/2019","4\/21\/2020","4\/21\/2020","507","First line","1","0","06\/06\/2022","Treatment completed","Established","15\/04\/2025","7\/21\/2025","","4\/16\/2025","1","0","0","1","0","3","0","0","0","0","1","100","2186","36.83230664","31-45","1","Low","0.498786459","0","on time","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The Patient is stable and virally suppressed; continue first-line ART, support breastfeeding with quarterly VL monitoring, reinforce adherence, and monitor BP\/weight and contraception needs.","What should be considered for ART treatment when no NCDs are recorded for this patient?","The Patient has no NCDs noted\u2014continue current first-line ART, keep routine NCD screening, watch for interactions and toxicities, support adherence, and maintain viral suppression.","What factors suggest a need to adjust the patient\u2019s ART regimen?","The Patient is stable and suppressed; with no NCDs, continue first-line ART, while maintaining routine NCD screening (BP, glucose, lipids, renal) and breastfeeding monitoring.","The model predicted no action with mixed signals: long time since diagnosis ~6.0 years and CD4 count 507 increase risk, while risk tier Low decrease risk. In our cohort, this balance aligned with a lower-risk decision.","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""],["0","1666700184","01\/01\/1970","59","168","143\/84","55","M","8\/25\/2008","8\/25\/2008","8\/25\/2008","20","First line","1","0","11\/05\/2019","Treatment completed","Established","04\/06\/2025","09\/04\/2025","","06\/04\/2025","0","0","0","1","0","2","0","0","0","0","1","100","6127","55.42231348","46-60","1","Low","0.342851262","0","on time","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The Patient remains virally suppressed but CD4 is 20\u2014confirm result, initiate PCP prophylaxis; address systolic hypertension and cardiovascular risk; continue first-line ART with close monitoring.","What should be considered for ART treatment when no NCDs are recorded for this patient?","The Patient is virally suppressed; continue first-line ART. Screen for hypertension (BP 143\/84) and other NCDs; anticipate drug-drug interactions with any future NCD treatments.","What factors suggest a need to adjust the patient\u2019s ART regimen?","The Patient has no NCDs recorded; continue first-line ART, but screen\/manage hypertension (BP 143\/84) and metabolic risks, and urgently reassess CD4 20 for OI prophylaxis.","The model predicted no action mainly because time since diagnosis (~16.8 years) increases risk. In our cohort, counterintuitively, CD4 20 was associated with lower risk, despite usually signaling worse disease. WHO clinical stage (1) decreases risk. Effects are mixed overall.","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""],["1","1666700284","01\/01\/1974","93.5","184","146\/95","51","M","12\/22\/2008","12\/22\/2008","7\/20\/2009","300","First line","1","0","07\/11\/2019","Treatment completed","Established","03\/06\/2025","09\/03\/2025","Diabetes","06\/03\/2025","0","0","0","1","0","2","0","0","0","0","1","100","6007","51.41957563","46-60","1","Low","0.473974239","0","on time","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The Patient is virologically suppressed; continue current ART, but optimize hypertension and diabetes control, review drug interactions (e.g., metformin\u2013dolutegravir), monitor renal\/cardiovascular risk, and reinforce adherence.","The patient has both HIV and Diabetes. How might this affect ART treatment or what considerations are important in managing this patient?","The Patient has diabetes, so prioritize cardio-metabolic safety: confirm DTG-based regimen, adjust metformin dosing, monitor kidneys, lipids and weight, and optimize BP; avoid PI-related dysglycemia.","What factors suggest a need to adjust the patient\u2019s ART regimen?","The Patient without NCDs can continue standard first-line ART; just confirm no contraindications or interactions, check renal\/hepatic function, and maintain viral load monitoring.","The model predicted no action mainly because time since diagnosis (~16.5 years) raises risk, and weight 93.5 kg raises risk, while WHO HIV stage 1 lowers risk. The drivers act in opposite directions, so effects are mixed in our cohort.","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""],["2","1666700307","12\/16\/1972","83","178","110\/68","52","M","1\/24\/2009","1\/26\/2009","10\/07\/2010","209","First line","1","0","03\/09\/2020","Treatment completed","Established","26\/06\/2025","9\/29\/2025","","6\/26\/2025","0","0","0","1","0","2","33.33333333","0","0","0","1","67","5997","52.52566735","46-60","1","High","0.36539938","0","on time","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The Patient is suppressed and stable; CD4 209\u2014borderline. Reinforce adherence (high IIT risk), consider PCP prophylaxis if trending <=200, and monitor cardiovascular\/metabolic risks.","What should be considered for ART treatment when no NCDs are recorded for this patient?","The Patient remains suppressed; continue first-line, but without recorded NCDs at 52, proactively screen, monitor ART toxicities, and adjust regimen only if comorbidity risks arise.","What factors suggest a need to adjust the patient\u2019s ART regimen?","The Patient can continue first-line ART; without NCDs, interactions are unlikely\u2014still perform routine NCD screening, renal\/hepatic labs and viral load monitoring, given age.","The model predicted no action mainly because weight (83 kg) raises risk, overall appointment success (67%) lowers risk, and time since diagnosis (~16.4 years) raises risk. These drivers pull in opposite directions, so effects are mixed for this patient.","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""],["3","1666700397","01\/01\/1961","115","184","137\/85","64","M","05\/12\/2009","06\/09\/2009","3\/21\/2011","256","First line","2","42","02\/11\/2016","Treatment completed","Established","12\/06\/2025","9\/15\/2025","Hypertension","06\/12\/2025","0","0","0","1","0","2","0","0","0","0","1","67","5875","64.44353183","61","1","Low","0.407239745","0","on time","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The Patient is virologically suppressed; let\u2019s keep current ART, tighten BP control, tackle obesity, assess cardiovascular risk, monitor CD4\/VL, and reinforce adherence and clinic retention.","The patient has both HIV and Hypertension. How might this affect ART treatment or what considerations are important in managing this patient?","The Patient\u2019s hypertension heightens CVD risk; I\u2019d favor INSTI-based ART, avoid boosted-PI\/antihypertensive interactions, and monitor renal function, electrolytes, lipids, weight, and blood pressure.","What factors suggest a need to adjust the patient\u2019s ART regimen?","The Patient can continue first-line ART; if no NCDs recorded, still screen for hypertension\/diabetes, check renal\/hepatic function and interactions, and reinforce adherence\/viral-load monitoring.","The model predicted no action mainly because time since diagnosis (~16.1 years) raises risk, weight 115 kg raises risk, while overall appointment success (66.7%) lowers risk. The drivers act in opposite directions, so effects are mixed.","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""],["4","1666700439","12\/10\/1964","64","165","129\/75","60","M","06\/12\/2009","06\/12\/2009","2\/21\/2010","329","First line","1","0","12\/02\/2019","Treatment completed","Established","17\/06\/2025","9\/15\/2025","","6\/17\/2025","0","0","0","1","0","2","0","0","0","0","1","100","5849","60.5174538","61","1","Low","0.465946235","0","late\/IIT","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The Patient is stable and virally suppressed; continue first-line ART, monitor VL\/CD4, and prioritize age-related comorbidity screening and adherence support given moderate IIT risk.","What should be considered for ART treatment when no NCDs are recorded for this patient?","The Patient appears stable; continue first-line ART, maintain undetectable VL, and routinely screen for age-related NCDs and drug interactions, adjusting only if new comorbidities emerge.","What factors suggest a need to adjust the patient\u2019s ART regimen?","The Patient has no recorded NCDs; continue first-line ART with age-appropriate NCD screening, renal\/hepatic monitoring, interaction checks, and maintain viral suppression.","The model predicted no action mainly because time since diagnosis (~16.0 years) and weight 64 kg raise risk, while WHO Stage 1 lowers risk. These effects oppose each other; two upward influences and one downward create a mixed picture.","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""],["5","1666700466","10\/02\/1975","95","162","136\/83","49","M","7\/26\/2010","7\/26\/2010","06\/02\/2011","294","First line","1","0","03\/02\/2016","Treatment completed","Established","07\/06\/2025","09\/06\/2025","Hypertension","06\/07\/2025","0","0","0","1","0","2","0","0","0","0","1","100","5430","49.68104038","46-60","1","Low","0.45449693","0","on time","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The Patient remains virally suppressed; continue current first\u2011line ART, but prioritize hypertension and obesity management, cardiovascular risk screening, drug\u2011interaction checks, and VL\/CD4 plus adherence monitoring.","The patient has both HIV and Hypertension. How might this affect ART treatment or what considerations are important in managing this patient?","The Patient\u2019s hypertension and obesity raise cardiovascular risk; choose ART with minimal metabolic\/renal impact, monitor BP, kidneys and lipids, and watch antihypertensive\u2013ART interactions.","What factors suggest a need to adjust the patient\u2019s ART regimen?","The Patient has no recorded NCDs, so standard DTG + TDF\/3TC first-line is fine; just keep routine renal\/hepatic checks, interaction review, and suppression monitoring.","The model predicted no action mainly because time since diagnosis (~14.9 years) raises risk, weight (95 kg) raises risk, and WHO HIV Stage 1 lowers risk. These drivers act in opposite directions, so effects are mixed in our cohort.","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""],["6","1666700821","6\/25\/1974","91.5","167","141\/80","51","M","7\/23\/2010","7\/23\/2010","7\/23\/2010","452","First line","1","0","03\/04\/2016","Treatment completed","Established","05\/06\/2025","09\/04\/2025","","06\/05\/2025","0","0","0","1","0","1","0","0","0","0","1","100","5431","50.94592745","46-60","1","Low","0.555121222","1","on time","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The Patient remains suppressed; continue ART. Confirm and manage hypertension, address obesity, assess ASCVD risk, monitor metabolic labs, and reinforce adherence given moderate interruption risk.","What should be considered for ART treatment when no NCDs are recorded for this patient?","The Patient is stable on first-line ART; despite no recorded NCDs, BP 141\/80 and BMI ~33 warrant cardiometabolic screening and regimens with lower weight\/lipid effects.","What factors suggest a need to adjust the patient\u2019s ART regimen?","The Patient has no recorded NCDs; continue first-line ART, but monitor BP and weight (BMI ~33) and cardiovascular risk; avoid agents worsening cardiometabolic profile.","The model predicted follow-up mainly because time since diagnosis (~14.9 years) increases risk, weight (91.5 kg) increases risk, and, counterintuitively, CD4 (452) was associated with higher risk though usually protective. All three drivers point the same way.","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""],["7","1666700989","01\/01\/1958","56","179","163\/88","67","M","12\/07\/2010","12\/20\/2010","2\/14\/2011","302","First line","1","0","01\/10\/2019","Treatment completed","Established","19\/06\/2025","9\/18\/2025","Hypertension","06\/09\/2025","-10","0","1","0","0","2","0","0","0","0","1","100","5308","67.46338125","61","1","Low","0.429523045","0","on time","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The Patient is virologically suppressed; I'd prioritize tighter BP control, address underweight, review adherence, consider statin, and assess renal\/bone health and interactions given age\/regimen.","The patient has both HIV and Hypertension. How might this affect ART treatment or what considerations are important in managing this patient?","The Patient has uncontrolled BP; let\u2019s optimize antihypertensives and check ART\u2013BP interactions. Prefer DTG-based therapy, avoid boosted PIs; monitor creatinine\/potassium with ACE\/ARB+TDF, lipids, ASCVD risk.","What factors suggest a need to adjust the patient\u2019s ART regimen?","The Patient can receive standard first-line ART; screen for NCDs (BP, glucose, renal\/hepatic function), check drug interactions, and individualize dosing for age and weight.","The model predicted no action mainly because time since diagnosis (~14.5 years) raises risk, WHO HIV stage 1 lowers risk, and, in our cohort, counterintuitively, overall appointment success (100%) was associated with higher risk. Effects are mixed.","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""],["8","1666701064","05\/10\/1971","59","165","138\/95","54","M","02\/01\/2011","2\/16\/2011","3\/21\/2011","342","First line","1","716639","01\/03\/2019","Treatment completed","Not Established","24\/07\/2025","9\/15\/2025","","8\/15\/2025","22","0","0","0","1","2","33.33333333","0","0","0","0","67","5287","54.20670773","46-60","1","High","0.266049728","0","on time","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The Patient has virologic failure (VL 716k); urgently assess adherence and resistance, likely switch regimen, manage elevated BP, reinforce retention, and update labs before changes.","What should be considered for ART treatment when no NCDs are recorded for this patient?","The Patient has no recorded NCDs; I\u2019d still screen\u2014BP 138\/95 suggests hypertension. Focus on adherence, repeat VL\/resistance, and optimize first-line ART (prefer DTG).","What factors suggest a need to adjust the patient\u2019s ART regimen?","The Patient has no recorded NCDs; still screen for hypertension\/ASCVD given BP 138\/95, optimize adherence, repeat viral load, and assess resistance with potential regimen switch.","The model predicted no action mainly because In our cohort, counterintuitively, viral load (716639) was associated with lower risk. Overall appointment success (66.7%) lowers risk, while time since diagnosis (~14.5 years) raises risk. Effects are mixed.","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""],["9","1666701084","10\/04\/1956","81.5","168","146\/78","68","M","03\/04\/2011","03\/04\/2011","02\/09\/2015","264","First line","1","0","3\/25\/2022","Treatment completed","Established","19\/06\/2025","9\/18\/2025","","6\/19\/2025","0","0","0","1","0","2","0","0","0","0","1","100","5221","68.7063655","61","1","Low","0.384682184","0","on time","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The Patient is virologically suppressed; continue ART. Optimize hypertension and weight; assess ASCVD risk and renal\/bone safety if on TDF; reinforce adherence and routine monitoring.","What should be considered for ART treatment when no NCDs are recorded for this patient?","The Patient has no recorded NCDs; keep current suppressed ART, but screen for hypertension (BP 146\/78), diabetes and lipids, and monitor renal\/bone health given age.","What factors suggest a need to adjust the patient\u2019s ART regimen?","The Patient has no documented NCDs; however, given age and BP 146\/78, consider screening for HTN\/diabetes\/CKD, monitor renal\/lipids, review interactions, and maintain first-line ART.","The model predicted no action mainly because time since diagnosis (~14.3 years) raises risk, WHO HIV stage 1 lowers risk, and weight 81.5 kg raises risk. The drivers act in opposite directions, so effects are mixed in our cohort.","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""],["10","1666701128","05\/07\/1980","82","170","110\/60","45","M","2\/25\/2012","2\/25\/2012","07\/03\/2014","106","First line","1","27200","12\/28\/2018","Treatment completed","Not Established","17\/06\/2025","9\/18\/2025","","6\/19\/2025","2","0","0","1","0","2","33.33333333","0","0","0","1","67","4861","45.11156742","46-60","1","High","0.396452007","0","on time","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The Patient has unsuppressed viremia and CD4 106; strengthen adherence, repeat VL, consider OI prophylaxis, arrange resistance testing, and switch to second-line if failure persists.","What should be considered for ART treatment when no NCDs are recorded for this patient?","The Patient has no recorded NCDs; prioritize managing viremia via EAC, repeat VL, consider resistance testing, AHD care, and continue NCD screening before regimen change.","What factors suggest a need to adjust the patient\u2019s ART regimen?","The Patient has no recorded NCDs; proceed with DTG-based first-line ART, urgently address adherence and high VL, and still screen for undiagnosed NCDs before changes.","The model predicted no action mainly because time since diagnosis (~13.3 years) and weight (82 kg) raise risk, while overall appointment success (66.7%) lowers risk. The drivers act in opposite directions, so effects are mixed in our cohort.","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""],["11","1666701131","8\/17\/1981","73","168","145\/93","44","M","3\/21\/2011","04\/04\/2011","05\/10\/2011","198","First line","1","0","08\/05\/2016","Treatment completed","Established","28\/06\/2025","9\/27\/2025","","6\/23\/2025","-5","0","1","0","0","2","0","0","0","0","1","100","5213","43.86310746","31-45","1","Low","0.354832286","0","on time","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The Patient is virologically suppressed but with CD4 198; consider PCP prophylaxis, optimize blood pressure and cardiovascular risk, review ART interactions, and support adherence.","What should be considered for ART treatment when no NCDs are recorded for this patient?","The Patient has no recorded NCDs; continue first-line ART, but re-screen hypertension (BP 145\/93), assess cardiovascular risk, and ensure OI prophylaxis given CD4 198.","What factors suggest a need to adjust the patient\u2019s ART regimen?","The Patient lacks recorded NCDs; continue standard first-line ART, but re-screen for NCDs. BP suggests hypertension; optimize BP control, check renal\/hepatic function, interactions, and adherence.","The model predicted no action mainly because time since diagnosis (~14.3 years) increases risk, WHO HIV stage 1 decreases risk, and, in our cohort, counterintuitively, CD4 198 was associated with lower risk despite being low. Overall, effects are mixed.","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""],["12","1666701152","01\/01\/1946","50.5","174","116\/70","79","M","4\/26\/2011","4\/28\/2011","5\/14\/2011","564","First line","1","26","4\/25\/2020","Treatment completed","Established","17\/06\/2025","9\/17\/2025","","6\/17\/2025","0","0","0","1","0","2","0","0","0","0","1","100","5166","79.45790554","61","1","Low","0.496871445","0","on time","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The Patient is virally suppressed; at 79 with BMI ~16.7, prioritize nutrition, geriatric review, interaction\/renal dosing checks, vaccinations, and reinforce adherence given predicted IIT risk.","What should be considered for ART treatment when no NCDs are recorded for this patient?","The Patient is virologically suppressed; continue current ART, but given age and low BMI, proactively screen for occult NCDs, renal\/hepatic issues, bone health, and interactions.","What factors suggest a need to adjust the patient\u2019s ART regimen?","The Patient is virologically suppressed; continue current ART, but proactively screen for occult NCDs and monitor renal and bone health given age and low BMI.","The model predicted no action mainly because Time since diagnosis (~14.1 years) increases risk. In our cohort, counterintuitively, overall appointment success (100%) and higher CD4 (564) were associated with higher risk. All three drivers point the same way.","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""],["13","1666701230","01\/02\/1974","107","173.7","123\/82","51","M","6\/22\/2011","6\/22\/2011","7\/22\/2011","314","First line","1","0","01\/11\/2019","Treatment completed","Established","12\/06\/2025","09\/08\/2025","","06\/09\/2025","-3","0","1","0","0","2","0","0","0","0","1","100","5104","51.44147844","46-60","1","Low","0.368230818","0","on time","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The Patient is stable with undetectable VL, CD4 314; continue ART. Prioritize obesity-related cardiometabolic screening, renal labs if on TDF, and reinforce adherence.","What should be considered for ART treatment when no NCDs are recorded for this patient?","The Patient has no recorded NCDs; continue current first-line ART, but proactively screen for cardiometabolic risks, monitor renal\/hepatic labs, address obesity, and reassess statin\/ASCVD risk.","What factors suggest a need to adjust the patient\u2019s ART regimen?","The Patient has no documented NCDs\u2014continue first-line ART; prioritize routine NCD screening, metabolic\/renal\/hepatic monitoring, and weight management given age and obesity to prevent future complications.","The model predicted no action mainly because time since diagnosis (~14 years) raises risk and weight 107 kg raises risk, while WHO stage 1 lowers risk. Effects are mixed, with two drivers pushing up and one pulling down.","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""],["14","1666701319","01\/01\/1968","65","171","145\/100","57","M","8\/25\/2011","09\/01\/2011","9\/24\/2011","389","First line","1","0","12\/13\/2018","Treatment completed","Established","02\/07\/2025","9\/30\/2025","","07\/02\/2025","0","0","0","1","0","2","0","0","0","0","1","100","5060","57.50034223","46-60","1","Low","0.443980994","0","late\/IIT","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The Patient remains virally suppressed on first-line ART; continue regimen, but address stage\u20112 hypertension, assess ASCVD risk, monitor renal\/lipids, and review ART\u2013antihypertensive interactions and adherence.","What should be considered for ART treatment when no NCDs are recorded for this patient?","The Patient has no recorded NCDs, but BP 145\/100 suggests hypertension; continue suppressed first-line ART, confirm NCDs, and ensure antihypertensive drug-drug compatibility, monitoring renal\/metabolic parameters.","What factors suggest a need to adjust the patient\u2019s ART regimen?","The Patient has no documented NCDs; continue first-line ART. Confirm and manage possible hypertension (BP 145\/100), screen for NCDs, check renal\/liver function, maintain viral-load monitoring.","The model predicted no action mainly because time since diagnosis (~13.9 years) raises risk, CD4 389 raises risk, and WHO stage 1 lowers risk. Effects are mixed here, with two drivers pushing up and one pulling down in our cohort.","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""],["15","1666701324","01\/01\/1977","81","169.3","118\/76","48","M","8\/30\/2011","09\/06\/2011","09\/06\/2011","254","First line","1","0","11\/14\/2019","Discontinued","Not Established","14\/06\/2025","9\/15\/2025","","6\/13\/2025","-1","0","0","1","0","2","0","0","0","0","1","100","5037","48.44900753","46-60","1","Low","0.439765429","0","on time","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The Patient is virally suppressed; CD4 254 implies suboptimal immune recovery\u2014monitor. Reassess halted TPT, address overweight\/cardiovascular risk, and reinforce adherence with routine VL\/CD4 monitoring.","What should be considered for ART treatment when no NCDs are recorded for this patient?","The Patient currently has no NCDs\u2014continue standard first-line ART; keep screening for NCDs, monitor renal\/hepatic function and lipids, check interactions, and maintain viral suppression.","What factors suggest a need to adjust the patient\u2019s ART regimen?","The Patient has no documented NCDs; maintain current suppressive first-line ART, but keep screening for NCDs, monitor renal\/hepatic function, and manage overweight\/cardiovascular risk.","The model predicted no action mainly because time since diagnosis (~13.8 years) and weight 81 kg raise risk, while WHO Stage 1 lowers risk. The drivers act in opposing directions, so overall effects are mixed for this patient.","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""],["16","1666701335","4\/24\/1981","92","185","122\/72","44","M","9\/21\/2011","9\/21\/2011","10\/24\/2011","233","First line","1","0","02\/09\/2016","Treatment completed","Established","25\/06\/2025","9\/25\/2025","","6\/25\/2025","0","0","0","1","0","2","0","0","0","0","1","100","5026","44.16974675","31-45","1","Low","0.408774448","0","on time","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The Patient remains virologically suppressed; let\u2019s monitor low CD4 (~233), optimize cardiovascular risk and weight, and continue adherence support with preventive care, including vaccinations.","What should be considered for ART treatment when no NCDs are recorded for this patient?","The Patient has no NCDs recorded; continue current first-line ART, maintain suppression, and plan routine NCD screening plus renal\/hepatic labs and cardiovascular risk assessment.","What factors suggest a need to adjust the patient\u2019s ART regimen?","The Patient is virologically suppressed on first-line ART; continue regimen, but ensure routine NCD screening, toxicity labs, adherence support, and cardiovascular risk monitoring.","The model predicted no action mainly because time since diagnosis (~13.8 years) raises risk, WHO HIV stage (1) lowers risk, and weight (92 kg) raises risk. The drivers act in opposite directions, so effects are mixed.","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""],["17","1666701424","01\/01\/1975","99","173","132\/88","50","M","12\/13\/2012","12\/13\/2012","12\/13\/2012","328","First line","1","0","12\/27\/2018","Treatment completed","Established","07\/06\/2025","09\/08\/2025","","06\/06\/2025","-1","0","0","1","0","2","33.33333333","0","0","0","1","67","4559","50.4312115","46-60","1","High","0.368469612","0","on time","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The Patient is virologically suppressed; continue ART, but address obesity\/elevated BP, modest CD4, reinforce adherence given IIT risk, and intensify cardiometabolic screening and counseling.","What should be considered for ART treatment when no NCDs are recorded for this patient?","The Patient is stable on first-line with undetectable VL; continue regimen, but screen for cardiometabolic disease given age, BMI ~33, and BP 132\/88 before decisions.","What factors suggest a need to adjust the patient\u2019s ART regimen?","The Patient has no recorded NCDs; continue DTG-based first-line if suppressed, but prioritize NCD screening, weight\/BP management, and interaction checks to mitigate cardiometabolic risk.","The model predicted no action mainly because weight (99 kg) raises risk, overall appointment success (67%) lowers risk, and time since diagnosis (~12.5 years) raises risk. Effects are mixed, with one driver lowering and two increasing risk.","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""],["18","1666701558","11\/19\/1973","77.5","170","127\/80","51","M","07\/02\/2012","07\/10\/2012","8\/23\/2012","301","First line","1","0","1\/16\/2019","Treatment completed","Established","04\/06\/2025","09\/04\/2025","Diabetes","06\/04\/2025","0","0","0","1","0","2","0","0","0","0","1","100","4720","51.54004107","46-60","1","Low","0.432867465","0","on time","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The Patient is stable and virally suppressed; continue ART, optimize diabetes control, address cardiometabolic risk, monitor CD4\/renal\/liver\/A1c\/lipids, and keep reinforcing adherence with routine follow-ups.","The patient has both HIV and Diabetes. How might this affect ART treatment or what considerations are important in managing this patient?","The Patient has diabetes; prioritize drug\u2013drug interactions (e.g., dolutegravir\u2013metformin), monitor glucose\/A1c, renal\/lipids, weight, cardiovascular risk, and adjust ART\/antidiabetics to optimize control.","What factors suggest a need to adjust the patient\u2019s ART regimen?","The Patient can start\/continue standard first-line TLD if no contraindications; still check renal\/hepatic function, interactions, TB screening, adherence readiness, and labs\/viral load monitoring.","The model predicted no action mainly because time since diagnosis (~12.9 years) raises risk, and body weight 77.5 kg raises risk, while the assigned risk tier (Low) lowers risk. The drivers act in opposite directions, so effects are mixed.","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""],["19","1666701571","11\/08\/1974","102","180","136\/98","50","M","7\/19\/2012","7\/28\/2012","10\/17\/2012","402","First line","1","0","12\/13\/2017","Treatment completed","Not Established","01\/07\/2025","9\/30\/2025","","6\/30\/2025","-1","0","0","1","0","2","0","0","0","0","1","100","4730","50.64476386","46-60","1","Low","0.359945245","0","on time","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The Patient is virologically suppressed on first-line ART; prioritize controlling hypertension and obesity, assess cardiovascular risk (lipids\/glucose, renal function), and continue adherence support and monitoring.","What should be considered for ART treatment when no NCDs are recorded for this patient?","The Patient lacks recorded NCDs, but obesity and diastolic hypertension warrant screening; continue first\u2011line ART, prefer TDF\u2011based over TAF\/boosted PI, monitor kidneys, lipids, blood pressure.","What factors suggest a need to adjust the patient\u2019s ART regimen?","The Patient has no NCDs recorded; elevated BP and obesity warrant screening. Continue ART minimizing cardiometabolic\/renal risk; avoid abacavir; if on TDF, monitor renal\/metabolic labs.","The model predicted no action mainly because weight (102 kg) raises risk, WHO stage 1 lowers risk, and time since diagnosis (~13.0 years) raises risk. Effects are mixed, with two drivers pushing up and one pulling down.","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""],["20","1666701632","1\/23\/1969","62","167","138\/84","56","M","10\/15\/2012","10\/22\/2012","11\/19\/2012","103","First line","1","663","11\/06\/2019","Treatment completed","Not Established","03\/06\/2025","09\/03\/2025","","06\/03\/2025","0","0","0","1","0","2","0","0","0","0","1","100","4614","56.35865845","46-60","1","Low","0.407802035","0","late\/IIT","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The Patient has CD4 103 and VL 663; prioritize adherence review, repeat VL, provide OI prophylaxis\/consider CrAg screen, and pursue resistance testing if viremia persists.","What should be considered for ART treatment when no NCDs are recorded for this patient?","The Patient has no recorded NCDs; still screen for hypertension, diabetes, CKD. Prefer metabolically neutral ART; assess renal\/cardiovascular risk, interactions, and adherence given VL 663.","What factors suggest a need to adjust the patient\u2019s ART regimen?","The Patient lacks recorded NCDs; continue\/optimize standard DTG-based first-line, emphasize adherence, repeat VL soon (663); screen for occult hypertension\/renal risk before any regimen changes.","The model predicted no action mainly because time since diagnosis (~12.6 years) raises risk. In our cohort, counterintuitively, CD4 103 was associated with lower risk despite typically reflecting worse immunity. WHO stage 1 lowers risk. Effects are mixed.","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""],["21","1666701669","12\/15\/1977","76","173","112\/63","47","M","11\/30\/2012","11\/30\/2012","02\/01\/2013","583","First line","1","0","12\/14\/2016","Treatment completed","Not Established","18\/08\/2025","9\/18\/2025","Diabetes","8\/18\/2025","0","0","0","1","0","2","0","0","0","0","1","100","4644","47.67419576","46-60","1","Low","0.532847141","1","on time","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The Patient remains suppressed; continue ART, integrate diabetes care; monitor A1c, renal function if on TDF, lipids\/weight; consider DTG-metformin interaction, manage CVD risk, reinforce adherence.","The patient has both HIV and Diabetes. How might this affect ART treatment or what considerations are important in managing this patient?","The Patient has diabetes\u2014choose low metabolic-risk ART; monitor glucose and renal function; watch interactions (INSTIs with metformin, boosted PIs with statins); manage cardiovascular risk.","What factors suggest a need to adjust the patient\u2019s ART regimen?","The Patient actually has diabetes recorded; if none, maintain current first-line ART, confirm baseline labs and renal\/hepatic status, screen for TB, and continue VL\/CD4 monitoring.","The model predicted follow-up mainly because time since HIV diagnosis (~12.7 years) raises risk. In our cohort, counterintuitively, CD4 count (583) was associated with higher risk. WHO HIV stage 1 lowers risk. Overall, effects are mixed.","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""],["22","1666701689","01\/01\/1964","61","171.4","102\/56","61","M","12\/21\/2012","12\/21\/2012","04\/08\/2013","85","First line","1","0","02\/06\/2016","Treatment completed","Established","04\/06\/2025","09\/04\/2025","","06\/04\/2025","0","0","0","1","0","1","0","0","0","0","1","100","4548","61.42368241","61","1","Low","0.372698872","0","on time","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The Patient is virologically suppressed but CD4 85; continue TMP-SMX prophylaxis, consider CrAg screen, evaluate immunologic nonresponse, reinforce adherence, and update vaccinations\/comorbidity screening.","What should be considered for ART treatment when no NCDs are recorded for this patient?","The Patient has no NCDs, so DTG-based first-line remains appropriate; screen for comorbidities, monitor renal\/bone health; with CD4 85 give cotrimoxazole, consider CrAg testing.","What factors suggest a need to adjust the patient\u2019s ART regimen?","The Patient has no recorded NCDs; continue current first-line ART, but keep age-appropriate NCD screening, renal\/hepatic monitoring, and OI prophylaxis given CD4 85.","The model predicted no action mainly because time since diagnosis (~12.5 years) raises risk. In our cohort, counterintuitively, CD4 85 was associated with lower risk despite being very low, and WHO Stage 1 lowers risk. Effects are mixed.","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""],["23","1666701734","01\/01\/1963","46","167","118\/84","62","M","2\/13\/2013","2\/13\/2013","2\/13\/2013","512","First line","1","0","12\/02\/2019","Treatment completed","Established","04\/06\/2025","09\/04\/2025","","06\/04\/2025","0","0","0","1","0","2","33.33333333","0","0","0","1","67","4494","62.42299795","61","1","High","0.324730897","0","on time","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The Patient is stable on ART with undetectable VL, but underweight; I'd focus on nutrition, age-appropriate comorbidity screening, renal\/bone checks, and adherence support.","What should be considered for ART treatment when no NCDs are recorded for this patient?","The Patient has no recorded NCDs\u2014continue current first-line ART; expect minimal drug interactions, but still screen regularly and monitor renal\/lipids and underweight status given age.","What factors suggest a need to adjust the patient\u2019s ART regimen?","The Patient is stable and suppressed; without NCDs recorded, continue first-line ART, but screen for hypertension, diabetes, renal\/liver issues, considering age and low BMI.","The model predicted no action mainly because overall appointment success (66.7%) lowers risk and time since diagnosis (~12.3 years) raises risk. In our cohort, counterintuitively, CD4 512 was associated with higher risk. Overall, effects are mixed.","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""],["24","1666701737","2\/26\/1968","73","173","117\/68","57","M","02\/07\/2013","2\/14\/2013","6\/17\/2013","56","First line","1","0","2\/15\/2016","Treatment completed","Established","25\/06\/2025","9\/25\/2025","","6\/23\/2025","-2","0","0","1","0","2","0","0","0","0","1","100","4521","57.32785763","46-60","1","Low","0.503644944","1","on time","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The Patient is virologically suppressed but CD4 56; I'd continue ART, ensure TMP-SMX prophylaxis, screen toxo\/CrAg, avoid live vaccines, and assess for immunologic nonresponse causes.","What should be considered for ART treatment when no NCDs are recorded for this patient?","The Patient can continue standard DTG-based first-line ART if tolerated; still screen for age-related NCDs, monitor renal\/hepatic function, and ensure OI prophylaxis given CD4 56.","What factors suggest a need to adjust the patient\u2019s ART regimen?","The Patient has no documented NCDs; continue first-line ART, screen for hypertension\/diabetes\/lipids, check interactions if NCDs start, and give OI prophylaxis given CD4 56.","The model predicted follow-up mainly because time since diagnosis (~12.4 years) increases risk, and weight (73 kg) increases risk. In our cohort, counterintuitively low CD4 (56) was associated with lower risk, despite being clinically concerning. Overall, effects are mixed.","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""],["25","1666701742","01\/01\/1963","74","166","145\/101","62","M","02\/05\/2013","2\/19\/2013","3\/15\/2013","244","First line","1","0","12\/02\/2019","Treatment completed","Established","04\/06\/2025","09\/04\/2025","Hypertension","06\/04\/2025","0","0","0","1","0","2","0","0","0","0","1","100","4502","62.42299795","61","1","Low","0.445231882","0","on time","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The Patient is virologically suppressed; address elevated BP, monitor renal function with ART\/antihypertensives, consider statin given age\/HIV, and maintain adherence support.","The patient has both HIV and Hypertension. How might this affect ART treatment or what considerations are important in managing this patient?","The Patient\u2019s hypertension is uncontrolled; let\u2019s prioritize BP control, keep suppressive ART, check interactions (boosters with CCBs\/statins), favor integrase-based regimens, and monitor renal\/metabolic risks.","What factors suggest a need to adjust the patient\u2019s ART regimen?","The Patient can continue standard first-line ART; confirm no hidden comorbidities, review drug interactions, and check renal\/hepatic function and blood pressure before any regimen changes.","The model predicted no action mainly because time since diagnosis (~12.3 years) increases risk, weight 74 kg increases risk, while WHO HIV Stage 1 decreases risk. The drivers act in opposite directions, so overall effects are mixed.","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""],["26","1666701783","8\/27\/1976","60","172","134\/83","49","M","4\/26\/2013","4\/26\/2013","5\/13\/2013","56","First line","1","838","12\/18\/2018","Treatment completed","Established","05\/06\/2025","09\/02\/2025","","06\/04\/2025","-1","0","0","1","0","2","33.33333333","0","0","0","1","67","4423","48.77207392","46-60","1","High","0.332199892","0","on time","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The Patient has CD4 56 and VL 838; intensify adherence support, start PCP prophylaxis with CrAg screening, repeat viral load, consider resistance-guided review if persistent.","What should be considered for ART treatment when no NCDs are recorded for this patient?","The Patient has no documented NCDs\u2014continue current first-line ART, intensify adherence support, repeat VL soon; given CD4 56, ensure OI prophylaxis and screen for NCDs.","What factors suggest a need to adjust the patient\u2019s ART regimen?","The Patient lacks recorded NCDs; a DTG-based first-line is reasonable, screen for HTN\/DM\/renal issues. CD4 56 needs OI prophylaxis; VL 838\u2014reinforce adherence, repeat VL.","The model predicted no action mainly because time since diagnosis (~12.1 years) increases risk. In our cohort, counterintuitively, CD4 56 was associated with lower risk despite being very low, and overall appointment success (66.7%) decreases risk. Effects are mixed.","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""],["27","1666701815","01\/01\/1950","82","167","138\/84","75","M","5\/29\/2013","6\/15\/2013","12\/08\/2018","162","First line","1","0","3\/18\/2017","Treatment completed","Established","11\/06\/2025","09\/10\/2025","","06\/11\/2025","0","0","0","1","0","2","0","0","0","0","1","100","4396","75.44147844","61","1","Low","0.294425193","0","on time","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The Patient is virologically suppressed; with CD4 162, consider TMP-SMX prophylaxis, optimize geriatric CV risks (BP\/weight), ensure vaccinations, monitor bone\/renal health, and continue current ART.","What should be considered for ART treatment when no NCDs are recorded for this patient?","The Patient is suppressed; keep first-line ART. Despite no NCDs, at 75 HTN\/DM\/CVD screening, review renal\/bone status, avoid abacavir with ASCVD risk, consider PCP prophylaxis.","What factors suggest a need to adjust the patient\u2019s ART regimen?","The Patient has no NCDs; continue first-line ART and, given age, keep screening BP, glucose, renal and hepatic function; monitor toxicity alongside undetectable viral load.","The model predicted no action mainly because time since diagnosis (~12.0 years) increases risk, while WHO stage 1 decreases risk. In our cohort, counterintuitively, low CD4 (162) was associated with lower risk. Effects are mixed.","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""],["28","1666701913","8\/17\/1983","57.5","163","99\/70","42","M","12\/23\/2013","01\/06\/2014","1\/17\/2014","333","First line","1","0","05\/09\/2016","Treatment completed","Established","18\/06\/2025","9\/17\/2025","","6\/18\/2025","0","0","0","1","0","2","33.33333333","0","0","0","1","67","4195","41.83709788","31-45","1","High","0.309656254","0","on time","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The Patient appears virally suppressed; let\u2019s continue first-line, reinforce adherence (high-risk), monitor CD4\/renal-liver, screen NCDs, and repeat viral load next visit. BP low-normal.","What should be considered for ART treatment when no NCDs are recorded for this patient?","The Patient has no NCDs recorded; continue first-line ART and keep routine NCD screening, monitoring renal\/hepatic function, cardiovascular risk, and potential drug\u2013drug interactions.","What factors suggest a need to adjust the patient\u2019s ART regimen?","The Patient has no recorded NCDs; continue current first-line ART, but keep routine NCD screening and cardiovascular risk assessment, and review interactions and organ function.","The model predicted no action mainly because overall appointment success (67%) lowers risk, time since diagnosis (~11.5 years) raises risk, and WHO clinical stage (1) lowers risk. The drivers act in opposite directions, so effects are mixed.","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""],["29","1666702017","8\/27\/1982","56.5","166","111\/72","43","M","5\/28\/2014","06\/12\/2014","07\/10\/2014","65","First line","1","0","12\/23\/2016","Treatment completed","Established","17\/06\/2025","9\/17\/2025","","6\/17\/2025","0","0","0","1","0","2","0","0","0","0","1","100","4038","42.80629706","31-45","1","Low","0.379967739","0","on time","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The Patient is suppressed on first-line, but CD4 65; I\u2019d continue ART, ensure cotrimoxazole, screen for OIs\/CrAg, check adherence and causes of poor immune recovery.","What should be considered for ART treatment when no NCDs are recorded for this patient?","The Patient has no recorded NCDs; continue current first-line ART with adherence support, routine renal\/hepatic monitoring, NCD screening; maintain OI prophylaxis given CD4 65.","What factors suggest a need to adjust the patient\u2019s ART regimen?","The Patient has no NCDs; continue first-line ART, maintain VL\/CD4 monitoring, screen for undiagnosed NCDs, and manage OI prophylaxis given low CD4.","The model predicted no action mainly because time since diagnosis (~11.1 years) raises risk. In our cohort, counterintuitively, CD4 count 65 was associated with lower risk despite being low. WHO stage 1 lowers risk. Effects are mixed.","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""],["","1458225657","8\/15\/1988","67","161","119\/76","37","F","3\/13\/2009","3\/13\/2009","3\/13\/2009","","Second line","1","0","07\/12\/2017","Treatment completed","Established","04\/07\/2025","10\/17\/2025","","07\/02\/2025","-2","0","0","1","0","3","0","0","0","0","1","100","5957","37","31-45","1","Low","0.41","0","on time","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The patient completed TB treatment, is on second line of ART therapy with valid viral load suppression. Regular CD4 monitoring remains crucial at this stage.","What should be considered for ART treatment when no NCDs are recorded for this patient?","The patient isn't presenting any noncommunicable diseases (NCDs), so the focus should remain on their HIV management and maintaining zero viral load.","What factors suggest a need to adjust the patient\u2019s ART regimen?","The patient's ART regimen may need adjustment given her robust success with the current treatment, indicated by a viral load of zero.","The model predicted no action mainly because time since diagnosis (approximately 16.3 years), a baseline CD4 result of 306, and height of 161 cm each raise risk factors in our cohort. All three drivers consistently point towards increased risk.","306","02\/07\/2025","Valid","Single Drug Substitution","04\/04\/2025","No","25\/01\/2018","3","0.008577865","-0.020417991","0.008383245","0.004103046","0.023578623","0.027363527","0.102875174","0.002697535","0.000204201","-0.001682689","0.000112258","0.00651531","0.003779192","-0.034996974","-0.001468018","-0.001245449","0.004547749","0.00255791","-0.00055576","0.000733232","-0.001879536","1.40E-06","0.00467911","0.000250498","-0.001083704","0.008358928","0.007199218","0.299334352","probability","1","0.59","time_since_diagnosis_at_scheduled_appointment","Baseline CD4 result","height","5957","306","161","increases","increases","increases","0","0","0","1","3","4","15"],["","1666700025","5\/17\/1978","73.5","178","126\/98","47","M","01\/02\/2009","01\/02\/2009","06\/08\/2015","","First line","1","0","7\/22\/2019","Treatment completed","Established","09\/07\/2025","10\/07\/2025","","07\/09\/2025","0","0","0","1","0","3","0","0","0","0","1","100","6032","47","46-60","1","Low","0.47","0","late\/IIT","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The patient completed TB treatment, has a stable viral load, and adherence to first-line HIV regimen. Regular monitoring of blood pressure is recommended.","What should be considered for ART treatment when no NCDs are recorded for this patient?","The patient doesn't have any NCDs, so focus on present HIV stage, viral load, and adherence to current first-line ART regimen for treatment decisions.","What factors suggest a need to adjust the patient\u2019s ART regimen?","The patient's viral load is currently undetectable, indicating that his first-line ART regimen seems to be effective, with no immediate need for adjustment.","The model predicted no action mainly because time since diagnosis (about 16.5 years), a baseline CD4 count of 230, and height (178 cm) each raise risk. All three drivers pointed the same way in our patient cohort.","230","09\/07\/2025","Invalid","Routine","16\/02\/2024","No","30\/07\/2019","2","0.010695839","-0.011704658","0.011030984","0.004677009","0.051818716","0.020236021","0.105103564","0.002768725","0.000300984","0.00351768","0.00066492","0.010413846","0.002345385","-0.02000795","0.008868337","0.006069211","0.006258256","0.007275599","0.01034756","0.001193237","-0.001435731","5.97E-07","0.007583612","0.009049361","-0.001199439","0.009229559","0.009173843","0.299334352","probability","1","0.53","time_since_diagnosis_at_scheduled_appointment","Baseline CD4 result","height","6032","230","178","increases","increases","increases","0","0","0","1","3","4","15"],["","1666700065","10\/18\/1957","64","157","131\/81","67","M","06\/12\/2008","06\/12\/2008","08\/12\/2008","","First line","1","0","03\/07\/2016","Treatment completed","Established","14\/07\/2025","10\/13\/2025","Hypertension","7\/14\/2025","0","0","0","1","0","3","0","0","0","0","1","100","6241","68","61","1","Low","0.47","0","late\/IIT","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The patient, being 67 years old and having hypertension, needs careful management of ART and antihypertensive medications to avoid potential drug interactions.","The patient has both HIV and Hypertension. How might this affect ART treatment or what considerations are important in managing this patient?","The patient's hypertension could potentially interact with ART, hence close monitoring is crucial to adjust treatment as required for optimized outcomes.","What factors suggest a need to adjust the patient\u2019s ART regimen?","The patient has a stable viral load of 0, suggesting the current ART regimen is effective. No immediate factors indicate a need for adjustment.","The model predicted no action mainly because time since diagnosis (about 17.1 years), CD4 result at baseline (224 cells\/mm\u00b3) and height (157 cm) each raise risk. All drivers align in the same direction, signifying a consistent increase in risk for this individual.","224","14\/07\/2025","Valid","Routine","14\/07\/2024","No","15\/08\/2016","2","0.005508212","-0.035930083","0.006513989","-0.00515831","0.020930043","0.023871611","0.096261762","0.001794226","0.000168264","-0.001092645","0.002195063","0.007957803","0.002803466","-0.027526494","0.004711561","0.004942317","0.004414679","-0.002313047","-0.004403041","-0.003253565","-0.002465781","7.94E-07","0.000544625","0.002757359","-0.001520945","0.008566549","0.007981187","0.299334352","probability","1","0.53","time_since_diagnosis_at_scheduled_appointment","Baseline CD4 result","height","6241","224","157","increases","increases","increases","0","0","0","1","3","4","14"],["","1666700291","01\/12\/1975","107","173","128\/78","50","M","12\/29\/2008","12\/29\/2008","03\/01\/2009","","First line","1","25","6\/20\/2020","Treatment completed","Established","12\/07\/2025","10\/11\/2025","","07\/12\/2025","0","0","0","1","0","3","0","0","0","0","1","100","6039","50","46-60","1","Low","0.39","0","on time","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The patient successfully completed TB treatment, is stable on first-line ART, has a low viral load, but doesn't have CD4 count data available.","What should be considered for ART treatment when no NCDs are recorded for this patient?","The patient has a successful first-line ART regimen, manageable blood pressure, and completed TB treatment. Monitor viral load and CD4 results closely while continuing ART.","What factors suggest a need to adjust the patient\u2019s ART regimen?","The patient's regimen might need adjusting if there's a significant change in CD4 counts, viral load, or evidence of drug side effects or intolerance.","The model predicted no action mainly because time since diagnosis (roughly 16.5 years), a Baseline CD4 result of 191, and a height of 173 cm each raise risk. All three drivers consistently point towards increased risk in our cohort.","191","12\/07\/2025","Valid","Routine","12\/04\/2025","No","28\/09\/2017","2","0.011916246","-0.010568793","0.002865406","0.005914982","0.057760111","0.018824444","0.087356699","0.002373301","0.000188373","0.001951468","0.001090634","0.007639395","0.00275612","-0.0253103","0.00734082","0.0090264","0.005798707","0.008193002","0.009393823","0.001056045","-0.001402076","5.10E-07","0.006282256","0.00714077","0.00010784","0.009381125","0.010709775","0.299334352","probability","1","0.61","time_since_diagnosis_at_scheduled_appointment","Baseline CD4 result","height","6039","191","173","increases","increases","increases","0","0","0","1","3","4","16"],["","1666701128","05\/07\/1980","82","170","110\/60","45","M","2\/25\/2012","2\/25\/2012","07\/03\/2014","","First line","1","27200","12\/28\/2018","Treatment completed","Not Established","18\/09\/2025","10\/01\/2025","","9\/18\/2025","0","0","0","1","0","3","25","0","0","0","1","75","4954","45","46-60","1","Medium","0.35","0","late\/IIT","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The patient successfully completed TB treatment, but the viral load is high and invalid, suggesting a need to potentially reassess the current HIV treatment regimen.","What should be considered for ART treatment when no NCDs are recorded for this patient?","The patient has no recorded NCDs, so the focus for ART treatment should primarily be monitoring viral load and current first line regimen's effectiveness.","What factors suggest a need to adjust the patient\u2019s ART regimen?","The patient's high viral load and the invalidity of the last viral load test might suggest a need for adjusting the current ART regimen.","The model predicted no action mainly because a high viral load (27200), a long time since diagnosis (~13.6 years), and being of a taller height (170 cm) each raise the risk. All three drivers consistently increase the risk in our cohort.","130","18\/09\/2025","Invalid","Routine","24\/05\/2024","No","25\/06\/2019","1","0.030584508","-0.004107586","-0.029388373","-0.00594944","0.062261043","-0.021274162","0.078489112","0.003922874","0.00090808","0.000753301","9.07E-07","0.008058848","0.001908688","-0.014994219","0.001560154","0.001396435","0.006116439","0.001504053","0.01232035","0.000805659","-0.001902349","2.91E-07","0.009032598","0.001676686","0.019137797","0.008186827","0.008390956","0.299334352","probability","1","0.65","Viral_Load","time_since_diagnosis_at_scheduled_appointment","height","27200","4954","170","increases","increases","increases","0","0","0","2","1","4","17"],["","1666701669","12\/15\/1977","76","173","112\/63","47","M","11\/30\/2012","11\/30\/2012","02\/01\/2013","","First line","1","0","12\/14\/2016","Treatment completed","Not Established","18\/09\/2025","10\/01\/2025","Diabetes","9\/18\/2025","0","0","0","1","0","3","75","1","0","1","1","25","4675","48","46-60","1","High","0.25","0","on time","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The patient, given his age, diabetic condition, and successful TB treatment history, may need regular monitoring and personal care during ART regimen.","The patient has both HIV and Diabetes. How might this affect ART treatment or what considerations are important in managing this patient?","The patient's diabetes may interact with ART, requiring careful monitoring of blood glucose levels and potential regimen adjustments to manage both conditions effectively.","What factors suggest a need to adjust the patient\u2019s ART regimen?","The patient's consistent on-time appointments, absence of a significant change in WHO HIV stage, and zero viral load suggest no need for adjusting the ART regimen.","The model predicted no action mainly because the time since diagnosis (roughly 12.8 years), the baseline CD4 result (583), and height (173 cm) all increase the risk. All three drivers point the same way, indicating a consistent upward pull in our cohort.","583","18\/09\/2025","Invalid","Routine","13\/05\/2024","No","08\/06\/2017","1","0.009852403","0.001746497","0.00627171","-0.004435363","0.049664731","-0.021726762","0.060153328","-0.028140171","0.002336152","0.000975951","-0.001069427","0.008949053","0.001758084","-0.026342218","0.006347425","0.004675382","0.003469489","0.004628608","0.008914731","-0.000294148","-0.002143964","2.12E-07","-0.001748347","-0.002204396","-0.000618402","0.007981809","0.006908521","0.299334352","probability","1","0.75","time_since_diagnosis_at_scheduled_appointment","Baseline CD4 result","height","4675","583","173","increases","increases","increases","0","0","0","1","3","4","17"],["","1666702032","01\/06\/1978","108","174","138\/84","47","M","07\/07\/2014","7\/21\/2014","11\/22\/2014","","First line","1","0","06\/03\/2017","Treatment completed","Established","19\/07\/2025","10\/11\/2025","","7\/19\/2025","0","0","0","1","0","3","0","0","0","0","1","100","4030","48","46-60","1","Low","0.4","0","late\/IIT","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The patient successfully completed the TB treatment and has a controlled viral load. Regular clinical appointments and regimen continuity must be ensured.","What should be considered for ART treatment when no NCDs are recorded for this patient?","The patient's current regimen, CD4 count, viral load, and overall health condition should guide the ART treatment, even without recorded NCDs.","What factors suggest a need to adjust the patient\u2019s ART regimen?","The patient's viral load is currently 0 and they are on their first line ART with a success flag of 1, suggesting no urgent need for ART regimen adjustment.","The model predicted no action mainly because time since diagnosis (~11 years), CD4 count (386 cells\/mm3), and height (174 cm) each raise risk. All three drivers point in the same direction, suggesting a consistent upward trend in risk.","386","19\/07\/2025","Valid","Routine","17\/10\/2024","No","11\/11\/2017","2","0.007690264","-0.021690939","0.008933867","0.012441592","0.064348652","0.018031905","0.090200714","0.002865496","0.000170795","0.002165861","0.00040382","0.007979762","0.002544831","-0.021371701","0.01036179","0.009647583","0.005853723","0.005697662","0.015157654","0.001639451","-0.001570767","6.02E-07","0.006905408","0.007722723","-0.000252305","0.009485119","0.01047925","0.299334352","probability","1","0.6","time_since_diagnosis_at_scheduled_appointment","Baseline CD4 result","height","4030","386","174","increases","increases","increases","0","0","0","1","3","4","15"],["","1666702238","12\/24\/1971","56","166","125\/84","53","M","4\/27\/2015","5\/14\/2015","1\/28\/2016","","First line","1","0","03\/11\/2016","Treatment completed","Established","12\/07\/2025","10\/14\/2025","","07\/12\/2025","0","0","0","1","0","3","0","0","0","0","1","100","3729","54","46-60","1","Low","0.45","0","late\/IIT","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The patient has completed TB treatment successfully and is maintaining a zero viral load. Regular monitoring of potential NCDs may be beneficial.","What should be considered for ART treatment when no NCDs are recorded for this patient?","The patient has already started first-line ART, so it's important to focus on monitoring their progress, adherence and any adverse reactions to treatment.","What factors suggest a need to adjust the patient\u2019s ART regimen?","The patient shows no immediate need for ART regimen adjustment as the viral load is zero, indicating successful treatment, and there's no late medication pick-ups.","The model predicted no action mainly because time since diagnosis (~10.2 years), a CD4 count of 270, and height (166 cm) all raise risk. These top three drivers consistently increase the potential for risk.","270","12\/07\/2025","Valid","Routine","10\/05\/2025","No","06\/09\/2016","3","0.004590715","-0.071007857","0.007881833","0.000279177","-0.007740189","0.017668426","0.107722073","0.002536197","0.000124194","-0.000411194","0.001440559","0.002248097","0.001444596","-0.018160897","0.003982652","0.003640464","0.000539987","0.001587822","-0.001700801","0.001057779","-0.002354713","1.54E-06","0.004981181","0.000594839","-0.003522619","0.007880491","0.009103689","0.299334352","probability","1","0.55","time_since_diagnosis_at_scheduled_appointment","Baseline CD4 result","height","3729","270","166","increases","increases","increases","0","0","0","1","3","4","15"],["","1666702242","07\/07\/1992","71","170","127\/70","33","M","5\/21\/2015","5\/21\/2015","3\/14\/2016","","First line","1","0","12\/14\/2016","Treatment completed","Established","14\/07\/2025","10\/13\/2025","","7\/14\/2025","0","0","0","1","0","3","0","0","0","0","1","100","3707","33","31-45","1","Low","0.36","0","on time","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The patient has been stable on first-line ART with successful completion of TB treatment and his recent viral load test shows undetectable levels.","What should be considered for ART treatment when no NCDs are recorded for this patient?","The patient already has successful ART treatment and no recorded NCDs. We should focus on maintaining current regimen and routinely monitor viral load.","What factors suggest a need to adjust the patient\u2019s ART regimen?","The patient's Viral Load is zero suggesting no immediate adjustment of ART regimen. However, do continue to monitor CD4 levels and overall health status regularly.","The model predicted no action mainly because time since diagnosis (around 10.2 years), baseline CD4 count (269), and height (170 cm) each raise risk in our cohort. These drivers all point in the same direction, indicating a consistent upward push on risk for this patient.","269","14\/07\/2025","Valid","Confirmation of treatment failure (repeat VL)","10\/12\/2024","No","14\/05\/2017","2","0.007829754","-0.03012778","0.007651394","-0.014764163","0.027209791","0.022205641","0.106484362","0.002118285","2.01E-05","-0.004766553","0.001133532","0.017897684","0.00287308","-0.028928692","0.003883772","0.003449661","0.002507356","-0.003321473","-0.005909399","0.000547851","-0.002289148","9.39E-07","0.005585661","-0.00959699","-0.003258685","0.008803184","0.009370258","0.299334352","probability","1","0.64","time_since_diagnosis_at_scheduled_appointment","Baseline CD4 result","height","3707","269","170","increases","increases","increases","0","0","0","1","3","4","14"],["","1666702470","2\/22\/1983","82.5","169","180\/136","42","M","04\/09\/2016","4\/20\/2016","08\/11\/2016","","First line","1","0","5\/17\/2017","Treatment completed","Established","19\/07\/2025","10\/18\/2025","Hypertension","7\/18\/2025","-1","0","0","1","0","3","0","0","0","0","1","100","3388","42","31-45","1","Low","0.33","0","on time","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The patient's hypertension and successful past adherence to treatments are critical to account for in managing his current HIV stage.","The patient has both HIV and Hypertension. How might this affect ART treatment or what considerations are important in managing this patient?","The patient's hypertension may have interactions with ART medication, requiring vigilant blood pressure management and regular monitoring for cardiovascular side-effects.","What factors suggest a need to adjust the patient\u2019s ART regimen?","The patient's zero viral load indicates a highly effective ART regimen. However, their elevated blood pressure might necessitate a regimen reassessment for possible interactions.","The model predicted no action mainly because the time since diagnosis (~9.3 years), a baseline CD4 result of 600, and the patient's height (169 cm) each raise risk. All three drivers consistently suggest a higher risk.","600","16\/10\/2024","Valid","Confirmation of treatment failure (repeat VL)","16\/10\/2024","No","30\/11\/2017","3","0.005772603","-0.026839489","0.006503539","-0.01055508","0.042242568","0.021435945","0.096624515","0.002311186","0.000400301","-0.004290288","0.001169617","0.017256909","0.00211311","-0.03415655","0.004189832","0.002413182","0.004226746","0.000721527","-0.006754218","0.00058395","-0.002169676","9.41E-07","0.004504674","-0.01037982","-0.003420269","0.008997297","0.009212018","0.299334352","probability","1","0.67","time_since_diagnosis_at_scheduled_appointment","Baseline CD4 result","height","3388","600","169","increases","increases","increases","0","0","0","1","3","4","15"],["","1322007302","8\/14\/1978","91","157","111\/80","47","F","11\/11\/2011","11\/11\/2011","10\/16\/2015","","Second line","1","0","","","Established","20\/08\/2025","11\/18\/2025","","8\/20\/2025","0","0","0","1","0","3","0","0","0","0","1","100","5031","47","46-60","1","Low","0.44","0","on time","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The patient is on the second line of ART, with an invalid last viral load test. Re-testing for viral load and monitoring closely is necessary.","What should be considered for ART treatment when no NCDs are recorded for this patient?","The patient has a steady routine for their second line ART regimen with no NCDs. While maintaining this, monitor their viral load and WHO HIV stage.","What factors suggest a need to adjust the patient\u2019s ART regimen?","The patient's CD4 count isn't available and their viral load results are invalid, indicating potential issues in response to the current second-line ART regimen.","The model predicted no action mainly because, although time since diagnosis (~14 years), a baseline CD4 result of 346, and height of 157 cm each incrementally raise risk, their cumulative effect didn't surpass the follow-up threshold. These are the top three among many features used by the model.","346","20\/08\/2025","Invalid","Routine","19\/07\/2024","No","","2","0.004946788","-0.045254189","0.005199918","-0.000572142","0.049603997","0.012754674","0.075546613","0.002670201","0.000295288","0.005537722","-0.000864802","0.011882108","0.000159832","-0.025145595","-0.00744122","-0.004877579","0.004046649","-0.002714875","0.005034526","0.001618722","-0.001925603","1.10E-06","0.003814925","-0.015800399","-0.002630872","0.008485429","0.009165686","0.299334352","probability","1","0.56","time_since_diagnosis_at_scheduled_appointment","Baseline CD4 result","height","5031","346","157","increases","increases","increases","0","0","0","1","2","4","14"],["","1530503160","04\/12\/1981","98","173","143\/96","44","F","6\/29\/2014","6\/29\/2014","6\/29\/2014","","Second line","1","0","7\/23\/2019","Treatment completed","Established","19\/08\/2025","11\/18\/2025","","8\/19\/2025","0","0","0","1","0","3","25","0","0","0","1","75","4069","44","31-45","1","Medium","0.37","0","on time","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The patient is on a second-line HIV regimen with a good response maintaining zero viral load. No active TB, adherence to ART appears successful.","What should be considered for ART treatment when no NCDs are recorded for this patient?","The patient has second-line ART treatment ongoing, stable WHO HIV stage 1 status, and a viral load at zero. These factors should guide their ART management.","What factors suggest a need to adjust the patient\u2019s ART regimen?","The patient's current blood pressure implies a need for adjusting the ART regimen, considering the progress in treatment and maintaining overall health.","The model predicted no action mainly because, although time since diagnosis (~11.1 years), a baseline CD4 result of 230, and a height of 173 cm all increase risk, these factors did not push the overall score above the follow-up threshold. These are the top three among many features used by the model.","230","19\/08\/2025","Valid","Routine","20\/05\/2025","No","15\/01\/2020","2","0.014392008","-0.027137582","0.002229536","-0.004826736","0.05006744","-0.026575204","0.063534458","0.00166367","0.000956735","-0.00012794","-0.002273928","0.00808205","0.00190656","-0.02814606","-0.001908345","-0.004357296","0.002403026","-0.001128051","-0.00503406","0.000785101","-0.002021087","6.09E-07","0.0021111","0.00113538","0.007655736","0.006789032","0.005474382","0.299334352","probability","1","0.63","time_since_diagnosis_at_scheduled_appointment","Baseline CD4 result","height","4069","230","173","increases","increases","increases","0","0","0","1","2","4","16"],["","1666700078","12\/23\/1975","64","152","116\/84","49","F","05\/05\/2008","05\/05\/2008","6\/30\/2008","","First line","1","0","12\/19\/2018","Treatment completed","Established","16\/08\/2025","11\/17\/2025","","8\/16\/2025","0","0","0","1","0","2","0","0","0","0","1","100","6312","50","46-60","1","Low","0.4","0","on time","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The patient completed TB treatment without subsequent issues, currently on first line HIV treatment. Viral load control excellent. Regular monitoring and continuing regimen is key.","What should be considered for ART treatment when no NCDs are recorded for this patient?","The patient has no recorded NCDs, so focus on maintaining current successful ART, considering First Line regimen and CD4 results. Regular viral load monitoring is essential.","What factors suggest a need to adjust the patient\u2019s ART regimen?","The patient's current first-line ART regimen seems effective, there's no indication of viral load increase or late arrivals. Thus, no urgent adjustments appear needed.","The model predicted no action mainly because, even though time since diagnosis (~17 years), CD4 count at 213, and a height of 152 cm each raise risk, collectively they did not tip the overall score over the follow-up threshold. These are the top three among many features used by the model.","213","16\/08\/2025","Valid","Routine","21\/08\/2024","No","13\/06\/2019","3","0.009172422","-0.031154975","0.006862297","-0.000586814","0.017121334","0.020753252","0.101229187","0.002763211","0.000196679","0.001249663","-0.00303648","0.008845109","0.001857275","-0.024158433","-0.0015786","-0.002022461","0.00336452","-0.00468336","-0.000100019","0.000884209","-0.002049792","1.05E-06","0.000217628","-0.004283693","0.000215142","0.007058211","0.007467317","0.299334352","probability","1","0.6","time_since_diagnosis_at_scheduled_appointment","Baseline CD4 result","height","6312","213","152","increases","increases","increases","0","0","0","1","2","4","14"],["","1666700458","05\/06\/1986","63.5","158.5","117\/75","39","F","07\/03\/2009","07\/03\/2009","8\/20\/2009","338","First line","1","0","03\/10\/2016","Treatment completed","Not Established","14\/08\/2025","11\/13\/2025","","8\/14\/2025","0","0","0","1","0","3","0","0","0","0","1","100","5886","39","31-45","1","Low","0.45","0","on time","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The patient completed TB treatment, currently on ART with stable HIV, and no known NCDs. Consistency in appointment adherence is excellent, maintain regular checkups.","What should be considered for ART treatment when no NCDs are recorded for this patient?","The patient has steadily maintained her CD4 count and her viral load is presently undetectable. Therefore, continuing the current first-line ART regimen seems advisable.","What factors suggest a need to adjust the patient\u2019s ART regimen?","The patient's viral load is currently stable at 0.0, indicating there's no urgent need to adjust the ART regimen at the moment.","The model predicted no action mainly because, although time since diagnosis (roughly 16 years), baseline CD4 result (345), and current CD4 count (338) each raise risk, their combined impact kept the score below the follow-up threshold. These are the top three among many features used by the model.","345","14\/08\/2025","Valid","Routine","16\/07\/2025","No","10\/08\/2016","2","0.005652036","0.00445269","0.006692541","0.004298784","0.004006809","0.019821867","0.097958356","0.002049248","0.000448539","0.003252837","-6.60E-05","0.003423929","0.003238269","-0.02829167","-0.001018555","-0.00043249","0.008507218","0.001013643","-0.002089684","0.000160728","-0.00232748","2.68E-06","-0.001448944","0.002398783","0.00044389","0.009328421","0.009040633","0.299334352","probability","1","0.55","time_since_diagnosis_at_scheduled_appointment","Baseline CD4 result","CD4_Count","5886","345","338","increases","increases","increases","0","0","0","1","2","3","15"],["","1666702189","8\/25\/1987","61.5","166","95\/67","38","F","2\/13\/2015","2\/27\/2015","04\/05\/2016","","First line","1","0","5\/16\/2016","Treatment completed","Established","16\/08\/2025","11\/17\/2025","","8\/16\/2025","0","0","0","1","0","3","0","0","0","0","1","100","3837","38","31-45","1","Low","0.41","0","on time","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The patient shows a stable condition with completed TB treatment, maintained first line ART and vigilance on viral load is essential. Regular follow-ups required.","What should be considered for ART treatment when no NCDs are recorded for this patient?","The Patient, on her first-line ART regimen, has no recorded NCDs. Considering her smooth past medication adherence, continue the current regimen, monitoring her response routinely.","What factors suggest a need to adjust the patient\u2019s ART regimen?","The patient's ART regimen might need adjustment if there were an increased viral load, change in WHO HIV stage, or CD4 count drop, which currently aren't observed.","The model predicted no action mainly because, although time since diagnosis (~10.5 years), a baseline CD4 result of 1495, and height (166.0 cm) each raise risk, their combined effects kept the score below the follow-up threshold. These are the top three among many features used by the model.","1495","16\/08\/2025","Invalid","Routine","17\/08\/2024","No","31\/10\/2016","3","0.009042497","-0.044443367","0.009884802","-0.001208703","0.013607123","0.025147044","0.107328846","0.002465233","0.000205726","-0.001354626","-0.000356112","0.005029008","0.004899497","-0.029685055","-4.55E-05","0.001965238","0.002178304","0.003696973","0.000172537","0.001016511","-0.002127878","4.95E-06","0.004280333","-0.004220549","-0.002003536","0.008248649","0.008333588","0.299334352","probability","1","0.59","time_since_diagnosis_at_scheduled_appointment","Baseline CD4 result","height","3837","1495","166","increases","increases","increases","0","0","0","1","2","4","14"],["","1666702353","6\/23\/1963","87","169","135\/85","62","M","10\/28\/2015","11\/05\/2015","6\/23\/2016","","First line","1","0","7\/23\/2019","Treatment completed","Established","07\/08\/2025","11\/13\/2025","","08\/07\/2025","0","0","0","1","0","3","0","0","0","0","1","100","3571","62","61+","1","Low","0.38","0","on time","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The patient has successfully completed TB treatment, has a valid viral load count of zero, and punctually adheres to appointments and treatments.","What should be considered for ART treatment when no NCDs are recorded for this patient?","The patient has been steady on the first line of ART since 2016 with no NCDs recorded. Focus on monitoring adherence and viral load.","What factors suggest a need to adjust the patient\u2019s ART regimen?","The patient's perfectly controlled viral load doesn't suggest a need for immediate adjustment of the current first-line ART regimen.","The model predicted no action mainly because time since diagnosis (approximately 9.8 years), patient's height (169 cm), and low baseline CD4 results (113) raise risk. Even so, their combined influence kept the overall score below the follow-up threshold. These are the top three among many features used by the model.","113","07\/08\/2025","Valid","Routine","05\/11\/2024","No","23\/07\/2019","3","0.0051869","-0.055155008","0.003787407","-0.006292875","0.034020818","0.012303346","0.077973943","0.001605579","-3.89E-05","0.000711717","0.002230098","0.008490363","0.00106229","-0.022241145","0.006273505","0.00808938","0.002839034","-0.004583726","-0.009879275","-0.008587586","-0.002508617","7.19E-07","0.000892587","-0.011011988","-0.001793774","0.007622391","0.009090736","0.299334352","probability","1","0.62","time_since_diagnosis_at_scheduled_appointment","height","Baseline CD4 result","3571","169","113","increases","increases","increases","0","0","0","1","4","2","15"],["","1666702370","10\/16\/1985","69.5","169","80\/139","40","M","11\/21\/2015","12\/09\/2015","12\/24\/2015","","First line","1","0","5\/13\/2017","Treatment completed","Established","16\/08\/2025","11\/15\/2025","","8\/16\/2025","0","0","0","1","0","3","0","0","0","0","1","100","3556","40","31-45","1","Low","0.4","0","on time","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The patient has a stable HIV stage with completed TB treatment. Regular monitoring is crucial, considering the invalid last viral load result.","What should be considered for ART treatment when no NCDs are recorded for this patient?","The patient has been stable on the first line ART regimen with a zero viral load. He maintains timely visits. So, continue the existing ART regimen.","What factors suggest a need to adjust the patient\u2019s ART regimen?","The patient's consistent zero viral load and stable health status doesn't indicate a need to adjust their current first line ART regimen.","The model predicted no action mainly because, although time since diagnosis (roughly 10 years), a baseline CD4 result of 518, and height of 169 cm each raise risk, their combined effect stayed below the follow-up threshold. These are the top three among many features used by the model.","518","16\/08\/2025","Invalid","Routine","24\/08\/2024","No","13\/11\/2017","2","0.007308244","-0.033875235","0.007191987","-0.010366463","0.026179621","0.025910503","0.112357991","0.002188798","0.000166744","-0.00340361","-0.000140853","0.01516474","0.002972712","-0.030683763","0.004299742","0.00243097","0.003347196","-0.00286994","-0.005005275","0.000376643","-0.002252292","9.57E-07","0.003955319","-0.008270508","-0.003260017","0.008695946","0.009991402","0.299334352","probability","1","0.6","time_since_diagnosis_at_scheduled_appointment","Baseline CD4 result","height","3556","518","169","increases","increases","increases","0","0","0","1","2","4","14"],["","1666703016","1\/17\/2001","54","170","98\/65","24","M","1\/28\/2020","1\/28\/2020","1\/28\/2020","","First line","1","23","2\/26\/2020","Treatment completed","Not Established","11\/08\/2025","11\/15\/2025","","08\/11\/2025","0","0","0","1","0","3","0","0","0","0","1","100","2022","25","18-30","1","Low","0.43","0","on time","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The patient responded well to first-line HIV therapy, with a low viral load. Regular check-ups are needed, focusing on noncommunicable diseases and adherence to ART.","What should be considered for ART treatment when no NCDs are recorded for this patient?","The patient has been on first-line ART since 2020 with a current valid viral load. The regimen appears effective without any recorded NCDs to consider.","What factors suggest a need to adjust the patient\u2019s ART regimen?","The patient's consistently low Viral Load and first-line regimen suggest no immediate need to adjust the ART regimen at this time.","The model predicted no action mainly because, although time since diagnosis (~18.4 years), baseline CD4 results (322), and height (170 cm) raise risk, their combined effect did not push the overall score above the follow-up threshold. These are the top three among many features used by the model.","322","11\/08\/2025","Valid","Routine","08\/05\/2025","No","12\/08\/2020","3","0.00876295","-0.056609829","0.003481676","0.002878739","0.002635096","0.024319441","0.105963208","0.002130336","0.000188807","-0.000898853","-0.00158524","0.009800081","0.003077143","-0.027659045","-0.000375847","0.000916105","-0.001172259","0.00260246","-0.000283083","0.001129316","-0.001975201","4.72E-06","0.006127527","-0.000508603","-0.001787904","0.008049336","0.008723743","0.299334352","probability","1","0.57","time_since_diagnosis_at_scheduled_appointment","Baseline CD4 result","height","2022","322","170","increases","increases","increases","0","0","0","1","2","4","16"],["","1666703321","12\/29\/2002","54","178.2","123\/87","22","M","7\/18\/2023","7\/18\/2023","9\/14\/2023","209","First line","1","0","2\/26\/2024","Treatment completed","Established","13\/08\/2025","11\/13\/2025","","8\/13\/2025","0","0","0","1","0","3","0","0","0","0","1","100","757","23","18-30","1","Low","0.31","0","on time","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The patient, with sustained viral suppression and a CD4 count of 209, requests routine monitoring. However, considering the patient's past history with TB, vigilance is needed.","What should be considered for ART treatment when no NCDs are recorded for this patient?","The patient, despite having no NCDs, needs consistent monitoring, adherence to the current first line of ART, and regular CD4 and viral load tests.","What factors suggest a need to adjust the patient\u2019s ART regimen?","The patient has a stable CD4 count and undetectable viral load, suggesting no immediate need to adjust the current first-line ART regimen.","The model predicted no action mainly because, even though the time since diagnosis (~2 years), CD4 count (209.0), and height (178.2 cm) all raise risk, their cumulative effect failed to push the overall score above the follow-up threshold. These are the top three among many features used by the model.","16","13\/08\/2025","Valid","Routine","13\/05\/2025","No","21\/05\/2024","3","0.004343692","-0.017603268","0.003985101","0.000895932","-0.014966444","0.011936083","0.0558169","0.001303095","0.000179009","0.000687119","0.002089791","0.00033684","0.004325371","-0.035787033","0.005249195","0.007548567","-0.01370449","0.003045575","-0.002040328","-0.001277708","-0.001901195","2.01E-07","-0.005415788","-0.016027929","0.000197885","0.006550884","0.007253544","0.299334352","probability","1","0.69","time_since_diagnosis_at_scheduled_appointment","CD4_Count","height","757","209","178.2","increases","increases","increases","0","0","0","1","3","4","15"],["","1666703496","6\/22\/2005","56","164","116\/63","20","F","6\/24\/2025","6\/24\/2025","6\/24\/2025","","First line","1","0","6\/24\/2025","On treatment","Established","15\/10\/2025","11\/14\/2025","","10\/15\/2025","0","0","0","1","0","3","25","0","0","0","1","75","113","20","18-30","1","Medium","0.11","0","on time","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The patient is currently on first-line ART treatment for HIV, stage 1, and also undergoing treatment for TB. Regular checkups, compliance with medications, and monitoring HIV stage progression are crucial.","What should be considered for ART treatment when no NCDs are recorded for this patient?","The patient currently shows no non-communicable diseases (NCDs). Thus, for ART treatment, consider their baseline CD4 result, current regimen line, and WHO HIV Stage.","What factors suggest a need to adjust the patient\u2019s ART regimen?","The patient's ART regimen may need adjustment if there's significant change in CD4 count, recurring illness, or persistent symptoms despite treatment.","The model predicted no action mainly because, while a Baseline CD4 result of 283, height of 164.0 cm, and time since diagnosis at approximately 3 months raise risk, their combined effect kept the overall score under the follow-up threshold. These are the top three among many features used by the model.","283","15\/10\/2025","","","","No","","0","0.006707585","-0.009636169","0.002039863","-0.002591609","-0.001910103","-0.032806265","-0.079758651","0.004687051","-0.000995955","0.005404311","-0.001033325","0.007094462","0.001378652","-0.036118779","-1.11E-05","-7.23E-05","0.001157095","-0.000515487","-0.000931651","-0.000211158","-0.001710727","1.16E-07","0.002590834","0.002397756","0.004881541","0.005776654","0.00570815","0.299334352","probability","1","0.89","Baseline CD4 result","height","time_since_diagnosis_at_scheduled_appointment","283","164","113","increases","increases","increases","0","0","0","2","4","1","14"],["","1287600384","23\/12\/1985","98","164","78\/116","39","F","02\/22\/2016","22\/04\/2016","07\/12\/2016","213","First line","1","75","23\/07\/2019","Treatment completed","Established","16\/09\/2025","12\/16\/2025","","09\/16\/2025","0","0","0","1","0","3","0","0","0","0","1","100","3494","40","31-45","1","Low","0.37","0","on time","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The patient is doing well on the first line of ART. We should continue monitoring her CD4 count and viral load consistently.","What should be considered for ART treatment when no NCDs are recorded for this patient?","The patient, who exhibits no NCDs, can continue with their current ART regimen. However, regular monitoring of CD4 count and viral load is recommended.","What factors suggest a need to adjust the patient\u2019s ART regimen?","The patient's ART regimen might need adjustment if there's a significant change in her CD4 count, viral load, or if she experiences severe side effects.","The model predicted no action mainly because, although time since diagnosis (~9.6 years) and CD4 count (213) raise risk, their collective effect did not push the overall score above the follow-up threshold. All three drivers point the same way. These are the top three among many features used by the model.","213","16\/09\/2025","Invalid","Routine","19\/09\/2024","No","30\/01\/2020","3","3","3","3","3","3","3","3","3","3","3","3","0.002924433","0.001367092","-0.029030452","-0.003184428","-0.002664278","0.008866027","0.002828422","-0.005719972","-0.000348291","-0.002361285","2.53E-06","-0.00409033","-0.01331853","-0.001556175","0.00587826","0.00539524","0.299334352","probability","1","0.63","time_since_diagnosis_at_scheduled_appointment","Baseline CD4 result","CD4_Count","3494","213","213","increases","increases","increases","0","0","0","2","3","4","16"],["","1544002247","22\/12\/2007","61.3","161","122\/60","17","M","07\/22\/2014","22\/07\/2014","02\/06\/2016","211","First line","1","74","16\/11\/2019","Treatment completed","Not Established","27\/09\/2025","12\/18\/2025","","09\/20\/2025","-7","0","1","0","0","3","0","0","0","0","1","100","4085","18","<18","1","Low","0.53","1","on time","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The Patient has a CD4 count of 211 and a stable, though detectable, viral load. This may require closer monitoring for potential treatment adjustment.","What should be considered for ART treatment when no NCDs are recorded for this patient?","The patient has consistently maintained a low viral load and a manageable CD4 count. For ART, consider the current regimen line and how well the patient's body is tolerating it. Ensure regular monitoring.","What factors suggest a need to adjust the patient\u2019s ART regimen?","The patient's low CD4 count of 211 might indicate a possible need for adjustment in the ART regimen, as it suggests the current treatment may not be fully effective.","The model predicted follow-up mainly because time since diagnosis (around 11 years), baseline CD4 result (817), and current CD4 count (211) each raise risk; collectively they pushed the score above the threshold. All three drivers point the same way. These are the top three among many features.","817","20\/09\/2025","Valid","Routine","20\/09\/2025","No","02\/01\/2018","2","2","2","2","2","2","2","2","2","2","2","2","-0.00649492","0.001057683","-0.019082292","0.006523747","0.01203198","0.007904862","0.00698978","-5.35E-05","1.95E-06","0.041521598","5.14E-06","0.002024008","0.005475242","0.001117103","0.008477847","0.009655388","0.299334352","probability","1","0.47","time_since_diagnosis_at_scheduled_appointment","Baseline CD4 result","CD4_Count","4085","817","211","increases","increases","increases","0","0","0","2","3","4","17"],["","1666700028","24\/05\/1976","67","159","146\/78","49","F","01\/01\/2007","01\/01\/2007","08\/01\/2007","300","First line","1","25","26\/11\/2019","Treatment completed","Established","20\/09\/2025","12\/18\/2025","Hypertension","09\/20\/2025","0","0","0","1","0","3","0","0","0","0","1","100","6837","49","46-60","1","Low","0.44","0","on time","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The patient is stable on first-line ART, and completed TB treatment successfully. Management should focus on managing hypertension, HIV treatment adherence, and regular viral load monitoring.","The patient has both HIV and Hypertension. How might this affect ART treatment or what considerations are important in managing this patient?","The patient might require careful ART regimen selection and monitoring to manage potential drug interactions and side-effects related to hypertension.","What factors suggest a need to adjust the patient\u2019s ART regimen?","The patient's CD4 count is stable and viral load is low, suggesting no immediate need to adjust the ART regimen. The hypertension could be monitored, though.","The model predicted no action mainly because, despite the fact that duration since diagnosis (~18.7 years), initial CD4 result (300), and current CD4 count (300) each raise risk, their collective effect remained below the follow-up threshold. All three drivers point the same way. These are the top three among many features used by the model.","300","20\/09\/2025","Valid","Routine","04\/10\/2025","No","20\/09\/2017","2","2","2","2","2","2","2","2","2","2","2","2","0.006659113","0.000843872","-0.024539583","7.23E-05","-0.002476439","0.011414313","0.004220654","0.014821882","0.000225081","-0.001968711","2.93E-06","-0.002577234","-0.003433547","0.001275265","0.010090564","0.011320206","0.299334352","probability","1","0.56","time_since_diagnosis_at_scheduled_appointment","Baseline CD4 result","CD4_Count","6837","300","300","increases","increases","increases","0","0","0","2","3","4","16"],["","1666701152","01\/01\/1946","50.5","174","116\/70","79","M","04\/26\/2011","28\/04\/2011","05\/14\/2011","205","First line","1","26","25\/04\/2020","Treatment completed","Established","17\/09\/2025","12\/16\/2025","","09\/17\/2025","0","0","0","1","0","3","0","0","0","0","1","100","5258","80","61+","1","Low","0.39","0","late\/IIT","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The patient has aged well with HIV and ART, but his low weight and CD4 count may necessitate a refined approach to maintaining health.","What should be considered for ART treatment when no NCDs are recorded for this patient?","The patient, with a stable CD4 count and viral load, seems responsive to the first-line ART. The absence of NCDs simplifies potential drug interactions.","What factors suggest a need to adjust the patient\u2019s ART regimen?","The patient has a stable first-line ART treatment with low viral load. Notably, only a significant change in CD4 count would warrant a regimen adjustment.","The model predicted no action mainly because, although time since diagnosis (approximately 14.4 years) and CD4 counts of 205 (both baseline and current) raise risk, their combined effect didn't push the overall score above the follow-up threshold. These are the top three among many features used by the model.","205","17\/06\/2025","Invalid","Routine","15\/06\/2024","No","30\/10\/2020","2","2","2","2","2","2","2","2","2","2","2","2","0.005907335","0.001500762","-0.021659515","0.005734147","0.007969784","0.003146539","-0.0004115","-0.001369532","0.003457664","-0.003486644","2.55E-05","0.005878027","-0.002939572","-0.000333264","0.007959839","0.008943758","0.299334352","probability","1","0.61","time_since_diagnosis_at_scheduled_appointment","Baseline CD4 result","CD4_Count","5258","205","205","increases","increases","increases","0","0","0","2","3","4","16"],["","1666701752","15\/02\/1965","59","162","66\/100","60","F","02\/28\/2013","15\/03\/2013","05\/13\/2013","419","First line","1","24","13\/12\/2018","Treatment completed","Not Established","17\/09\/2025","12\/16\/2025","","09\/17\/2025","0","0","0","1","0","3","0","0","0","0","1","100","4584","61","61+","1","Low","0.51","1","on time","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The patient, with a stable HIV stage 1 progression and good adherence to first line ART, can continue the same regimen barring any unexpected changes.","What should be considered for ART treatment when no NCDs are recorded for this patient?","The patient's current CD4 count, viral load, blood pressure, and adherence to first line regimen should be considered for ART treatment.","What factors suggest a need to adjust the patient\u2019s ART regimen?","The patient's viral load and CD4 count have remained stable, and they've consistently followed their treatment regimen. There's currently no necessity to adjust their ART regimen.","The model predicted follow-up mainly because time since diagnosis (~12.6 years), baseline CD4 result (419), and CD4 count (419) each raise risk. These risk-raising factors pushed the score above the threshold. All three drivers point the same way. These are the top three among many features used by the model.","419","19\/05\/2025","Valid","Routine","19\/05\/2025","No","20\/06\/2019","2","2","2","2","2","2","2","2","2","2","2","2","0.007088712","-0.001178187","-0.017788616","-0.00178186","0.000137242","0.008746207","0.00287242","-0.002535076","0.008920072","-0.002889534","2.57E-06","-0.000191588","0.000377994","0.00334825","0.013007458","0.013863055","0.299334352","probability","1","0.49","time_since_diagnosis_at_scheduled_appointment","Baseline CD4 result","CD4_Count","4584","419","419","increases","increases","increases","0","0","0","2","3","4","16"],["","1666701967","07\/11\/1981","58","154","101\/75","44","F","03\/28\/2014","28\/03\/2014","04\/25\/2014","366","First line","1","20","03\/08\/2019","Treatment completed","Established","20\/09\/2025","12\/17\/2025","","09\/20\/2025","0","0","0","1","0","3","0","0","0","0","1","100","4194","44","31-45","1","Low","0.47","0","on time","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The patient has completed TB treatment, maintains good CD4 count and shows insignificant viral load. Regular monitoring and adherence to first line ART is crucial.","What should be considered for ART treatment when no NCDs are recorded for this patient?","The patient shows responsive behaviour and is diligent regarding the ART treatment. So, it's crucial to continue the current regimen and monitor the viral load.","What factors suggest a need to adjust the patient\u2019s ART regimen?","The patient's viral load appears well controlled, with no reported non-communicable diseases or late arrivals for appointments. Currently, there's no clinical indication to adjust the ART regimen.","The model predicted no action mainly because, although time since diagnosis (~11.5 years) and CD4 counts (both baseline and current at 366) raise risk, these impacts did not sufficiently increase the overall score to necessitate a follow-up. These are the top three among many features used by the model.","366","22\/03\/2025","Invalid","Routine","15\/06\/2024","No","14\/08\/2019","2","2","2","2","2","2","2","2","2","2","2","2","-0.001022482","0.002120482","-0.026838585","-0.000375706","-0.00043604","0.007484833","0.002704584","-0.000288753","0.000258788","-0.002456143","6.00E-06","-0.00195769","-0.002457174","0.001713035","0.009983577","0.009114177","0.299334352","probability","1","0.53","time_since_diagnosis_at_scheduled_appointment","Baseline CD4 result","CD4_Count","4194","366","366","increases","increases","increases","0","0","0","2","3","4","16"],["","1666701980","18\/02\/1974","62.5","158.5","86\/113","51","F","03\/31\/2014","15\/04\/2014","05\/06\/2014","339","First line","1","38","23\/01\/2019","Treatment completed","Established","17\/09\/2025","12\/16\/2025","","09\/17\/2025","0","0","0","1","0","3","0","0","0","0","1","100","4188","52","46-60","1","Low","0.46","0","on time","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The patient has a stable HIV condition, with first-line treatment and negligible viral load, but attentiveness to her blood pressure control is necessary.","What should be considered for ART treatment when no NCDs are recorded for this patient?","The patient has an established regimen and no recorded NCDs. Their latest CD4 count and viral load indicate a good response to the current ART treatment.","What factors suggest a need to adjust the patient\u2019s ART regimen?","The patient's ART regimen remains appropriate given their stable CD4 count, low viral load, and lack of late arrivals to clinic appointments.","The model predicted no action mainly because, although time since diagnosis (~11.4 years) and a baseline as well as current CD4 result (339) raise risk, their summed effect kept the overall score below the threshold for follow-up. All three drivers point the same way. These are the top three among many features used by the model.","339","17\/09\/2025","Invalid","Routine","15\/02\/2024","No","24\/07\/2019","2","2","2","2","2","2","2","2","2","2","2","2","0.005049664","0.000954273","-0.022572042","-0.001101401","-0.000129131","0.010007025","0.00159934","0.00925129","-7.51E-05","-0.002321773","2.23E-06","-0.002143718","-0.007113243","0.000294405","0.011485045","0.012237088","0.299334352","probability","1","0.54","time_since_diagnosis_at_scheduled_appointment","Baseline CD4 result","CD4_Count","4188","339","339","increases","increases","increases","0","0","0","2","3","4","16"],["","1666702063","19\/10\/1975","59","164.5","73\/111","50","F","08\/13\/2014","13\/08\/2014","09\/24\/2014","256","First line","1","37","23\/01\/2019","Treatment completed","Established","17\/09\/2025","12\/16\/2025","Asthma","09\/17\/2025","0","0","0","1","0","3","0","0","0","0","1","100","4053","50","46-60","1","Low","0.51","1","on time","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The patient's consistent adherence to treatment, First line regimen, and controlled HIV-Stage 1 are positive signs, yet attention should be given to her asthma management.","What general considerations should be taken into account for ART treatment in this patient?","The patient has completed TPT, managed Asthma, is on first-line ART, with stable invalid viral loads, enjoying timely appointments. Focus on adherence and monitoring viral loads.","What factors suggest a need to adjust the patient\u2019s ART regimen?","The patient's current ART regimen seems effective as her viral load is low, CD4 count is stable, and there aren't any late arrivals or issues with medication adherence.","The model predicted follow-up mainly because both time since diagnosis (~11.1 years) and CD4 count (256) raise risk; their combined effect, along with the baseline CD4 result (256) which also raises risk, pushed the overall score above the threshold. All three drivers point the same way. These are the top three among many features used by the model.","256","17\/09\/2025","Invalid","Routine","18\/06\/2024","No","30\/04\/2019","2","2","2","2","2","2","2","2","2","2","2","2","0.004240126","0.000368211","-0.019196924","0.00115518","0.000853993","0.013348923","0.001359796","0.021954949","0.001137655","-0.002191957","3.42E-06","-0.003125243","-0.004623707","0.001088396","0.009225992","0.009484287","0.299334352","probability","1","0.49","time_since_diagnosis_at_scheduled_appointment","Baseline CD4 result","CD4_Count","4053","256","256","increases","increases","increases","0","0","0","2","3","4","16"],["","1666702104","05\/02\/1978","65.5","157","78\/134","47","F","10\/16\/2014","31\/10\/2014","12\/10\/2014","305","First line","1","68244","16\/02\/2016","Treatment completed","Established","18\/09\/2025","12\/17\/2025","","09\/18\/2025","0","0","0","1","0","3","0","0","0","0","1","100","3990","48","46-60","1","Low","0.41","0","on time","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The patient's elevated viral load requires close monitoring. Continue their first-line treatment and ensure regular timely check-ups to track progress. No signs of TB noted.","What should be considered for ART treatment when no NCDs are recorded for this patient?","The patient, having no NCDs, should primarily focus on maintaining ART adherence, monitoring CD4 count, viral load and managing potential side-effects of the treatment.","What factors suggest a need to adjust the patient\u2019s ART regimen?","The patient's current viral load of 68244 could necessitate an adjustment in their ART regimen if it indicates insufficient viral suppression.","The model predicted no action mainly because viral load (68244), time since diagnosis (roughly 11 years), and baseline CD4 result (305) each raise risk, but these factors didn't push the score over the threshold. All three drivers point the same way. These are the top three among many features.","305","18\/09\/2025","Valid","Routine","18\/09\/2025","No","15\/07\/2016","2","2","2","2","2","2","2","2","2","2","2","2","0.001360082","0.000685676","-0.013359618","0.001666651","-0.000971789","0.008807623","-0.001807762","0.009023157","-0.000208945","-0.002864815","9.03E-07","-0.010694249","-0.007741496","0.002278314","0.006079888","0.00527483","0.299334352","probability","1","0.59","Viral_Load","time_since_diagnosis_at_scheduled_appointment","Baseline CD4 result","68244","3990","305","increases","increases","increases","0","0","0","1","2","3","16"],["","1808800658","15\/09\/1998","46","159","95\/71","27","M","07\/26\/2013","26\/07\/2013","07\/26\/2013","37","First line","2","123783","03\/03\/2022","Treatment completed","Not Established","12\/11\/2025","12\/17\/2025","","11\/17\/2025","5","0","0","0","1","3","50","0","0","0","0","50","4492","27","18-30","1","High","0.28","0","on time","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The patient has a high viral load and low CD4 count, implying a less controlled HIV stage, suggesting an adjustment to their first-line ART regimen may be needed.","What should be considered for ART treatment when no NCDs are recorded for this patient?","The patient's low CD4 count, high viral load, and previous late arrivals might increase the complexity of the ART treatment, despite no recorded NCDs.","What factors suggest a need to adjust the patient\u2019s ART regimen?","The patient's high viral load and low CD4 count suggest a need to potentially adjust the ART regimen. Their consistent late arrivals may also be concerning.","The model predicted no action mainly because, although a high viral load (123783), time since diagnosis (~12.3 years), and height (159 cm) each raise risk, the combined effect did not exceed the follow-up threshold. These are the top three among many features used by the model.","71","17\/11\/2025","Valid","Routine","13\/10\/2025","No","26\/05\/2022","1","1","1","1","1","1","1","1","1","1","1","1","0.007061069","-0.000752632","-0.023228704","0.00338718","0.002727185","-0.006856691","0.00096608","-0.001721572","-0.000200228","-0.004321467","2.12E-07","0.001866271","0.000480829","0.000243297","0.006091256","0.007413392","0.299334352","probability","1","0.72","Viral_Load","time_since_diagnosis_at_scheduled_appointment","height","123783","4492","159","increases","increases","increases","0","0","0","1","2","5","18"],["","1057653957","05\/05\/1985","91","163","122\/63","40","F","06\/25\/2015","25\/06\/2015","07\/03\/2015","330","First line","1","0","03\/02\/2020","Treatment completed","Established","21\/10\/2025","01\/20\/2026","","10\/21\/2025","0","0","0","1","0","3","0","0","0","0","1","100","3771","40","31-45","1","Low","0.44","0","on time","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The patient appears stable on first line ART, has a controlled viral load, is not facing TB issues, and consistently schedules medical appointments - all positive signs.","What should be considered for ART treatment when no NCDs are recorded for this patient?","The patient shows consistent HIV medication compliance. In absence of NCDs, focus on viral load, CD4 count, and potential ART side effects during treatment.","What factors suggest a need to adjust the patient\u00e2\u20ac\u2122s ART regimen?","The patient's viral load is currently controlled and CD4 count is stable, suggesting no immediate need to adjust the current first-line ART regimen.","The model predicted no action mainly because, even though the span since diagnosis (approximately 10.3 years) and a CD4 count of 330 twice over each raise risk, they didn't amalgamate to push the score above the threshold for follow-up. These are the top three among many features used by the model.","330","21\/10\/2025","Valid","Routine","04\/02\/2025","No","12\/01\/2016","2","-0.00105","-0.00296","0.005841","0.015862","0.018737","0.016794443","0.102479934","0.001811","0.000562","0.007689","-0.00021","0.002628","0.001256","-0.02817","-0.00283","0.000686","0.010296","0.002845","-0.00311","0.000453","-0.0021","2.77E-06","-0.00115","-0.0095","-0.00071","0.003697","0.00501","0.299334352","probability","1","0.56","time_since_diagnosis_at_scheduled_appointment","Baseline CD4 result","CD4_Count","3771","330","330","increases","increases","increases","0","0","0","1","3","4","15"],["","1451700736","15\/06\/1999","80.5","160","130\/81","26","F","01\/24\/2020","24\/01\/2020","01\/24\/2020","98","First line","1","0","23\/06\/2022","Treatment completed","Established","03\/10\/2025","01\/02\/2026","","10\/03\/2025","0","0","0","1","0","3","0","0","0","0","1","100","2079","26","18-30","1","Low","0.32","0","on time","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The patient has responded well to first-line ART and TB treatment, maintaining good adherence. Regular follow-up and monitoring CD4 counts and viral load is essential.","What should be considered for ART treatment when no NCDs are recorded for this patient?","The patient has a stable regimen with good compliance, no co-infections, and undetectable viral load. So, just continue current first-line ART, maintaining regular monitoring.","What factors suggest a need to adjust the patient\u00e2\u20ac\u2122s ART regimen?","The patient has a valid last viral load result of zero and is consistently on-time for appointments, suggesting no immediate need to adjust the ART regimen.","The model predicted no action mainly because, although time since diagnosis (roughly 5.7 years) and height (160 cm) raise risk, in our cohort, counterintuitively, overall appointment success (100%) was associated with higher risk. Nonetheless, the total score remained below the follow-up threshold. These are the top three among many features used by the model.","98","03\/10\/2025","Valid","Confirmation of treatment failure (repeat VL)","06\/06\/2025","No","20\/09\/2022","2","0.001932","-0.06125","0.005258","0.000668","0.020708997","0.011548297","0.096017","0.001292","0.000135","0.011379","0.00278","0.00982","-0.00185","-0.03895","-0.00206","-0.00441","-0.02839","-0.00291","-0.00716","0.0014","-0.00226","1.39E-06","-0.00229","0.000884","-0.00128","0.005754","0.005525","0.299334352","probability","1","0.68","time_since_diagnosis_at_scheduled_appointment","height","overall_appointment_success","2079","160","100","increases","increases","increases","0","0","0","1","5","6","16"],["","1666700528","08\/06\/1974","73","179","130\/81","51","M","08\/19\/2009","19\/08\/2009","09\/14\/2009","300","First line","1","0","27\/02\/2016","Treatment completed","Not Established","22\/10\/2025","01\/22\/2026","Diabetes","10\/11\/2025","-11","0","1","0","0","3","0","0","0","0","1","100","5908","51","46-60","1","Low","0.47","0","on time","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The patient displays good adherence to first-line ART and has a well-controlled HIV status. However, diabetes and aging should factor in the treatment adjustments.","The patient has both HIV and Diabetes. How might this affect ART treatment or what considerations are important in managing this patient?","The patient's diabetes may impact ART's effectiveness, so consistent blood sugar monitoring and ART adherence are key to effective dual management.","What factors suggest a need to adjust the patient\u00e2\u20ac\u2122s ART regimen?","The patient's consistent CD4 count, zero viral load, and completed tuberculosis treatment suggest that an adjustment to the ART regimen isn't necessary.","The model predicted no action mainly because, although time since diagnosis (~16 years) and baseline CD4 result (300) raise risk, in our cohort, counterintuitively, a consistent CD4 count (300) was associated with a higher risk. Despite these factors, the overall score remained below the follow-up threshold. These are the top three among many features used by the model.","300","11\/10\/2025","Valid","Routine","25\/04\/2025","No","25\/08\/2016","3","0.007713","-0.00796","0.005441","0.00285","0.031323","0.018779424","0.08093","0.002337","0.000453","0.009886","-0.00112","0.002411","-0.0009","-0.01607","0.005625","0.003227","0.004197","0.007442","0.012080428","-0.00027","-0.00211","8.41E-07","-0.00095","-0.01833","-0.0028","0.011423954","0.010324424","0.299334352","probability","1","0.53","time_since_diagnosis_at_scheduled_appointment","Baseline CD4 result","CD4_Count","5908","300","300","increases","increases","increases","0","0","0","1","3","4","16"],["","1666701094","05\/11\/1962","52","175","116\/66","63","M","02\/24\/2012","02\/03\/2012","03\/23\/2012","220","First line","1","27","04\/01\/2019","Treatment completed","Established","22\/10\/2025","01\/21\/2026","","10\/23\/2025","1","0","0","1","0","3","0","0","0","0","1","100","4989","63","61+","1","Low","0.42","0","on time","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The Patient has a stable First line regimen and controlled viral load, but due to his age, careful attention to potential NCDs is essential.","What should be considered for ART treatment when no NCDs are recorded for this patient?","The patient has been on the first line of ART since 2012 with a stable CD4 count and a low viral load, showing a positive response.","What factors suggest a need to adjust the patient\u00e2\u20ac\u2122s ART regimen?","The patient's viral load and CD4 count are in control, suggesting no immediate need to adjust the current first line ART regimen.","The model predicted no action mainly because, although time since diagnosis (~14 years), baseline CD4 result (220), and current CD4 count (220) raise risk, their combined effect did not push the score above the follow-up threshold. These are the top three among many features.","220","23\/10\/2025","Valid","Routine","23\/10\/2025","No","25\/07\/2019","2","0.0041","-0.0276","0.010005","0.007618","-0.01616","0.014923306","0.095333","0.001625","0.000205","-0.00562","0.001906","0.005565","0.001248","-0.02051","0.007448","0.008926","0.002728","0.003195","0.000284","0.010918276","-0.0029","4.52E-06","0.003634","-0.00289","-0.00071","0.009844","0.011000668","0.299334352","probability","1","0.58","time_since_diagnosis_at_scheduled_appointment","Baseline CD4 result","CD4_Count","4989","220","220","increases","increases","increases","0","0","0","1","3","4","17"],["","1666701634","28\/11\/1978","80","153","121\/83","47","F","10\/01\/2012","23\/10\/2012","10\/28\/2013","340","First line","1","12189","15\/02\/2016","Treatment completed","Established","21\/10\/2025","01\/20\/2026","","10\/23\/2025","2","0","0","1","0","3","0","0","0","0","1","100","4768","47","46-60","1","Low","0.37","0","late\/IIT","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The patient should maintain the first-line ART regimen and regular monitoring of CD4 count and viral load is essential. Patient's punctuality for appointments is commendable.","What should be considered for ART treatment when no NCDs are recorded for this patient?","The patient has been on the first line of ART since 2013, has a stable CD4 count and a valid viral load. Therefore, maintain the current regimen.","What factors suggest a need to adjust the patient\u00e2\u20ac\u2122s ART regimen?","The patient's high viral load of 12189 indicates a potential need to adjust their current first-line ART regimen. Let's discuss best possible interventions.","The model predicted no action mainly because, while viral load (12189), time since diagnosis (~13 years), and baseline CD4 result (340) each raise risk, their combined effect did not push the overall score above the follow-up threshold. These are the top three among many features used by the model.","340","23\/10\/2025","Valid","Routine","23\/10\/2025","No","06\/08\/2016","2","0.005667","-0.00082","-0.02842","-0.00812","0.027773264","0.016878","0.075466","0.001624","0.000524","0.002925","-0.00039","0.000964","-0.0011","-0.01407","-0.00251","-0.00245","0.003897","-0.00228","0.006433","-0.00069","-0.00274","7.68E-07","-0.00661","-0.0221","-0.00022","0.008498","0.00788","0.299334352","probability","1","0.63","Viral_Load","time_since_diagnosis_at_scheduled_appointment","Baseline CD4 result","12189","4768","340","increases","increases","increases","0","0","0","2","1","3","17"],["","1666702333","13\/04\/1987","77","159","159\/103","38","F","10\/01\/2015","01\/10\/2015","10\/01\/2015","304","First line","1","0","22\/07\/2019","Treatment completed","Not Established","21\/10\/2025","01\/21\/2026","Hypertension","10\/21\/2025","0","0","0","1","0","3","0","0","0","0","1","100","3673","39","31-45","1","Low","0.38","0","late\/IIT","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The patient completed TB treatment and has controlled HIV, but hypertension remains a consideration. Regular, close monitoring of blood pressure is essential.","The patient has both HIV and Hypertension. How might this affect ART treatment or what considerations are important in managing this patient?","The patient's hypertension may influence ART drug selection to avoid harmful interactions, and consistent monitoring is vital for effective simultaneous management.","What factors suggest a need to adjust the patient\u00e2\u20ac\u2122s ART regimen?","The patient's blood pressure is high and the viral load validation indicated confirmation of treatment failure, suggesting the need to adjust their ART regimen.","The model predicted no action mainly because, despite the fact that time since diagnosis (approximately 10 years) and CD4 counts at baseline and current (both at 304) raise risk, these factors did not push the overall score above the follow-up threshold. These are the top three among many features used by the model.","304","21\/10\/2025","Valid","Confirmation of treatment failure (repeat VL)","28\/01\/2025","No","24\/07\/2019","3","-0.00117","-0.00818","0.003622","0.000163","0.000751","0.013979","0.098632","0.00184","0.000504","0.005083","-0.00142","0.003392","0.001806","-0.02467","-0.0032","-0.00288","0.008432","-0.00205","-0.00583","0.000105","-0.00284","2.68E-06","-0.00316","-0.01572","-0.0011","0.005029","0.004768","0.299334352","probability","1","0.62","time_since_diagnosis_at_scheduled_appointment","Baseline CD4 result","CD4_Count","3673","304","304","increases","increases","increases","0","0","0","1","3","4","15"],["","1666702340","12\/08\/1977","67","156","142\/77","48","F","08\/11\/2015","11\/08\/2015","08\/11\/2015","482","First line","1","0","31\/05\/2017","Treatment completed","Established","18\/10\/2025","01\/17\/2026","","10\/18\/2025","0","0","0","1","0","3","0","0","0","0","1","100","3721","48","46-60","1","Low","0.58","1","on time","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The patient has completed TB treatment, maintains a stable first-line HIV regimen, and has a healthy CD4 count. Regular check-ups remain crucial.","What should be considered for ART treatment when no NCDs are recorded for this patient?","The patient has a stable ART regimen with consistent viral suppression. Consider CD4 count, adherence to treatment, and possible side effects for further management.","What factors suggest a need to adjust the patient\u00e2\u20ac\u2122s ART regimen?","The patient is responding well to the first-line ART regimen with a viral load of 0 and an on-time treatment record. Currently, no adjustment seems necessary.","The model predicted follow-up mainly because time since diagnosis (about 10.2 years), baseline CD4 result (482 cells), and current CD4 count (482 cells) each raise risk; together they pushed the score above the threshold. All three drivers point the same way. These are the top three among many features used by the model.","482","18\/10\/2025","Invalid","Routine","06\/07\/2024","No","15\/11\/2017","2","0.012741767","0.061767","0.006504","-0.00727","0.005524","0.024290698","0.102922372","0.00195","0.000615","0.006706","0.001128","0.002784","0.001081","-0.01536","-0.00032","0.000628","0.011560762","0.012749368","0.024132","-0.00013","-0.00263","7.85E-07","0.004886","0.005006","0.000313","0.007724","0.008127","0.299334352","probability","1","0.42","time_since_diagnosis_at_scheduled_appointment","Baseline CD4 result","CD4_Count","3721","482","482","increases","increases","increases","0","0","0","1","3","4","16"],["","1666702351","11\/11\/1958","64","170","139\/77","67","M","11\/02\/2015","03\/11\/2015","11\/14\/2015","184","First line","1","0","09\/02\/2016","Treatment completed","Established","18\/10\/2025","01\/17\/2026","","10\/18\/2025","0","0","0","1","0","3","0","0","0","0","1","100","3638","67","61+","1","Low","0.39","0","on time","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The patient has a controlled viral load, no active TB and adheres well to first line ART. It's essential to routinely monitor CD4 count and general health.","What should be considered for ART treatment when no NCDs are recorded for this patient?","The patient, with a current regimen of first-line ART and no NCDs, should continue the same treatment, maintaining checkups for viral load and CD4 count regularly.","What factors suggest a need to adjust the patient\u00e2\u20ac\u2122s ART regimen?","The patient has a viral load of 0, suggesting the current ART regimen is effective. No immediate adjustments appear necessary based on current data.","The model predicted no action mainly because time since diagnosis (~10 years), a baseline CD4 result of 184, and a CD4 count of 184 each raise risk. However, their combined effect did not push the overall score above the follow-up threshold. These are the top three among many features used by the model.","184","18\/10\/2025","Valid","Confirmation of treatment failure (repeat VL)","18\/01\/2025","No","29\/07\/2016","2","0.003835","-0.05088","0.000762","-0.01377","0.017292","0.013241615","0.103189836","0.001295","0.000147","-1.75E-05","0.001038","0.004527","-8.12E-06","-0.02349","0.013495913","0.010861201","0.002695","0.008382","-0.00739","-0.00052","-0.00266","8.19E-07","-0.00176","-0.00491","0.002309","0.007208","0.007921","0.299334352","probability","1","0.61","time_since_diagnosis_at_scheduled_appointment","Baseline CD4 result","CD4_Count","3638","184","184","increases","increases","increases","0","0","0","1","3","4","16"],["","1666702876","03\/03\/1987","58","179","135\/90","38","M","11\/27\/2018","27\/11\/2018","12\/10\/2018","236","First line","1","18519","08\/01\/2019","Discontinued","Established","23\/10\/2025","01\/22\/2026","","10\/23\/2025","0","0","0","1","0","3","25","0","0","0","1","75","2522","39","31-45","1","Medium","0.25","0","late\/IIT","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The patient is engaged in first line ART, with a stable viral load but his blood pressure is slightly elevated. This needs careful monitoring.","What should be considered for ART treatment when no NCDs are recorded for this patient?","The patient, with no NCDs and a baseline CD4 count of 236, has been positively responding to the first line ART regimen. Keep monitoring CD4 and viral loads.","What factors suggest a need to adjust the patient\u00e2\u20ac\u2122s ART regimen?","The patient's relatively high viral load and the discontinuation of TPT indicate that an ART regimen adjustment might be necessary.","The model predicted no action mainly because viral load (18519), time since diagnosis (~7 years), and baseline CD4 (236) each raise risk; however, their combined impact did not cross the follow-up threshold. All three drivers increase risk. These are the top three among many features used by the model.","236","23\/10\/2025","Valid","Routine","23\/10\/2025","No","14\/05\/2019","2","0.026837","-0.01903","-0.0551","0.009132","-0.00368","-0.074","0.06057","0.005151","0.001528","-0.00098","-0.00137","0.001745","0.000463","-0.01698","0.004614","0.005268","-0.00038","-0.00437","-0.00171","-0.00046","-0.00405","9.12E-07","0.00391","0.003172","0.005823","0.004952","0.004566","0.299334352","probability","1","0.75","Viral_Load","time_since_diagnosis_at_scheduled_appointment","Baseline CD4 result","18519","2522","236","increases","increases","increases","0","0","0","2","1","3","19"],["","1666703140","12\/12\/1980","85","176","147\/98","45","F","04\/06\/2021","04\/06\/2021","04\/06\/2021","170","First line","1","78","28\/02\/2022","Lost to followup","Not Established","20\/10\/2025","01\/17\/2026","Hypertension","10\/18\/2025","-2","0","0","1","0","3","0","0","0","0","1","100","1658","45","31-45","1","Low","0.34","0","on time","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The patient, with HIV and hypertension, is fairly stable but lost to follow-up during TPT. Adherence may need encouragement and monitoring.","The patient has both HIV and Hypertension. How might this affect ART treatment or what considerations are important in managing this patient?","The patient's hypertension could influence ART choice due to potential drug interactions, necessitating careful monitoring and tailored therapy for effective HIV management.","What factors suggest a need to adjust the patient\u00e2\u20ac\u2122s ART regimen?","The patient's lower CD4 count and high blood pressure, along with their lost follow up on TPT suggest a need to adjust the ART regimen.","The model predicted no action mainly because the time since diagnosis (around 4.5 years), a Baseline CD4 count of 211, and the patient's height (176 cm) all raise risk. Yet, these factors combined didn't push the score above the threshold for follow-up. These are the top three among many features used by the model.","211","18\/10\/2025","Valid","Routine","18\/10\/2025","No","25\/05\/2022","2","0.000802","-0.04872","0.003768","0.007075","0.031058518","0.0125649","0.079557","0.001142","-0.00011","0.006899","-0.00047","-0.00032","0.001161","-0.02392","-0.00558","-0.00274","0.004248","0.001615","-0.00537","0.000116","-0.00236","6.53E-07","-0.00246","-0.03196","-0.00349","0.005934","0.008048","0.299334352","probability","1","0.66","time_since_diagnosis_at_scheduled_appointment","Baseline CD4 result","height","1658","211","176","increases","increases","increases","0","0","0","1","3","5","17"],["","1321800794","07\/07\/1980","65","160","101\/62","45","F","03\/14\/2012","03\/14\/2012","03\/14\/2012","321","Second line","1","67334","07\/06\/2017","Treatment completed","Not Established","24\/11\/2025","02\/24\/2026","NONE","11\/24\/2025","0","0","0","1","0","3","0","0","0","0","1","100","5003","45","46-60","1","Low","0.39","0","on time","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The Patient has high VL on second-line; I'd assess adherence\/interactions, repeat VL, get resistance testing, and plan third-line if failure confirmed, while maintaining OI screening.","What general considerations should be taken into account for ART treatment in this patient?","The Patient is on second-line with VL 67k; likely failure. Prioritize EAC, repeat VL in 8\u00e2\u20ac\u201c12 weeks, do genotyping, plan third-line; review interactions, toxicities, contraception.","What factors suggest a need to adjust the patient\u00e2\u20ac\u2122s ART regimen?","The Patient has a high viral load (67,334) on second-line ART despite on-time care, suggesting virologic failure\/resistance\u00e2\u20ac\u201dreview adherence and consider switch pending resistance testing.","The model predicted no action mainly because viral load (67k), diagnosis (~13.7 years), and CD4 (321) each increases risk, but score stayed below the follow-up threshold; all align. These are the top three among many features used by the model.","321","24\/11\/2025","Valid","Routine","25\/07\/2025","No","07\/12\/2017","3","0.01026","-0.00314","-0.04403","0.006679","0.004725","0.026753","0.078705","0.001465","0.000471","-0.00122","0.002077","0.000279","0.000376","-0.0138","0.000719","-0.00052","0.008301","-0.00042","0.009915","0.000463","-0.0023","9.63E-07","-0.0068","-0.00825","0.001468","0.008046","0.007811","0.299334352","probability","1","0.61","Viral_Load","time_since_diagnosis_at_scheduled_appointment","Baseline CD4 result","67334","5003","321","increases","increases","increases","0","0","0","1","2","3","16"],["","1535100471","15\/06\/1974","67","163","149\/88","51","F","01\/09\/2012","01\/09\/2012","01\/09\/2012","421","Second line","1","0","14\/01\/2019","Treatment completed","Established","22\/11\/2025","02\/21\/2026","Hypertension","11\/22\/2025","0","0","0","1","0","3","0","0","0","0","1","100","5066","51","46-60","1","Low","0.54","1","on time","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The Patient is virologically suppressed on second-line ART; continue regimen and adherence support. Blood pressure 149\/88 suggests uncontrolled hypertension\u00e2\u20ac\u201doptimize antihypertensives, check interactions, monitor renal\/metabolic parameters.","The patient has both HIV and Hypertension. How might this affect ART treatment or what considerations are important in managing this patient?","The Patient has hypertension and higher CV risk\u00e2\u20ac\u201dprefer DTG-based ART; if on boosted PI, adjust CCB\/statins; monitor renal\/K+ with TDF plus ACEi\/ARB; aim BP <130\/80.","What factors suggest a need to adjust the patient\u00e2\u20ac\u2122s ART regimen?","The Patient is suppressed and clinically stable, so no ART change now; adjust only if antihypertensive choices create interactions or adverse effects emerge.","The model predicted follow-up mainly because time since diagnosis (~13.9 years), baseline CD4 (421), and CD4 count (421) raise risk, pushing the score above threshold. All three drivers point the same way. These are the top three among many features used by the model.","421","22\/11\/2025","Valid","Routine","31\/01\/2025","No","26\/07\/2019","2","0.009206","0.045269","0.007337","0.016326","0.005405","0.020752","0.089338","0.002612","0.000598","-0.00472","0.00212","0.010134","-0.00023","-0.01893","-0.00068","0.000823","0.011624","0.002721","0.012748","0.000261","-0.0019","1.41E-06","0.003859","0.001346","-0.00155","0.011998","0.012498","0.299334352","probability","1","0.46","time_since_diagnosis_at_scheduled_appointment","Baseline CD4 result","CD4_Count","5066","421","421","increases","increases","increases","0","0","0","2","3","4","15"],["","1666700068","29\/10\/1984","67","167","110\/68","41","F","06\/16\/2008","06\/16\/2008","01\/06\/2015","140","First line","1","62","27\/07\/2019","Treatment completed","Established","27\/11\/2025","02\/25\/2026","NONE","11\/27\/2025","0","0","0","1","0","3","0","0","0","0","1","100","6373","41","31-45","1","Low","0.32","0","late\/IIT","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The Patient is virologically suppressed; continue same ART, reinforce adherence; CD4 140 warrants OI prophylaxis; consider multi-month dispensing and standard viral load follow-up.","What general considerations should be taken into account for ART treatment in this patient?","The Patient is stable with suppressed VL; continue first-line with adherence support, monitor VL\/renal labs, consider PCP prophylaxis at CD4 140, and review contraception\/pregnancy plans.","What factors suggest a need to adjust the patient\u00e2\u20ac\u2122s ART regimen?","The Patient is virally suppressed (VL 62), WHO stage 1, stable and adherent, with no toxicity or comorbidities\u00e2\u20ac\u201dso there\u00e2\u20ac\u2122s no current need to adjust ART.","The model predicted no action mainly because time since diagnosis (~17 years), height 167 cm, and CD4 140 each increase risk; however, the score stayed below follow-up threshold. These are the top three among many features used by the model.","140","27\/11\/2025","Valid","Routine","04\/10\/2025","No","30\/01\/2020","2","0.002901","-0.0535","-0.00239","-0.00681","0.007458","0.013272","0.089093","0.001768","0.000254","0.001666","3.16E-05","0.006121","0.002407","-0.03728","-0.00426","0.000246","0.004286","-8.46E-05","-0.00669","0.000203","-0.00252","1.70E-06","0.000354","-0.0103","-0.00082","0.008831","0.007672","0.299334352","probability","1","0.68","time_since_diagnosis_at_scheduled_appointment","height","Baseline CD4 result","6373","167","140","increases","increases","increases","0","0","0","2","5","3","17"],["","1666701205","04\/02\/1960","59","190","75\/53","66","M","05\/24\/2011","06\/06\/2011","07\/01\/2011","303","First line","1","139","07\/01\/2019","Treatment completed","Not Established","01\/10\/2025","02\/23\/2026","NONE","11\/21\/2025","51","1","0","0","1","3","25","0","0","1","0","75","5244","66","61+","1","Medium","0.37","0","late\/IIT","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The Patient needs urgent evaluation for hypotension and low BMI, repeat VL given IIT and invalid last result, plus renal\/hepatic labs to continue first-line ART.","What general considerations should be taken into account for ART treatment in this patient?","The Patient is hypotensive and underweight; urgently assess causes, support adherence after IIT, repeat invalid VL, review toxicity\/interactions, address nutrition, and continue first-line if tolerated\/suppressed.","What factors suggest a need to adjust the patient\u00e2\u20ac\u2122s ART regimen?","The Patient\u00e2\u20ac\u2122s prolonged first-line use, invalid VL with recent interruption, and marked hypotension\/underweight together raise concern for intolerance or resistance, so I\u00e2\u20ac\u2122d reassess the regimen.","The model predicted no action mainly because ~14 years post-diagnosis and two CD4 results (303 each) raise risk; score stayed below follow-up threshold. All drivers align. These are the top three among many features used by the model.","303","21\/11\/2025","Invalid","Routine","20\/06\/2024","No","24\/04\/2023","3","0.003826","-0.00048","0.004928","0.01728","0.002273","-0.04351","0.0531","0.005701","0.001267","-0.0063","-0.0012","0.007179","-0.00074","-0.01739","0.00285","0.003775","0.002179","0.005544","-0.00192","0.008796","-0.00238","1.44E-06","0.002871","-0.00097","0.005217","0.007748","0.010154","0.299334352","probability","1","0.63","time_since_diagnosis_at_scheduled_appointment","Baseline CD4 result","CD4_Count","5244","303","303","increases","increases","increases","0","0","0","2","3","4","19"],["","1666701914","01\/01\/2013","33","139","0\/0","13","F","12\/02\/2013","12\/19\/2013","12\/19\/2013","231","First line","1","48","12\/02\/2016","Treatment completed","Established","24\/11\/2025","02\/21\/2026","NONE","11\/24\/2025","0","0","0","1","0","3","0","0","0","0","1","100","4375","13","<18","1","Low","0.51","1","late\/IIT","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The Patient is virologically suppressed and stable; continue DTG-based regimen with 33-kg weight-band dosing, consider multi-month dispensing, and monitor growth\/puberty, adherence, vitals, and annual VL.","What general considerations should be taken into account for ART treatment in this patient?","The Patient is a virally suppressed 13-year-old; continue first\u00e2\u20ac\u2018line ART, ensure weight\u00e2\u20ac\u2018appropriate DTG\u00e2\u20ac\u2018based regimen, monitor growth\/renal\u00e2\u20ac\u2018bone health, adherence, psychosocial support, annual VL, and sexual\/reproductive counseling.","What factors suggest a need to adjust the patient\u00e2\u20ac\u2122s ART regimen?","The Patient remains suppressed (VL 48) and WHO 1\u00e2\u20ac\u201dno regimen change indicated, unless not yet transitioned to weight-appropriate DTG-based first-line for >30 kg adolescents.","The model predicted follow-up mainly because time since diagnosis (~12 years), baseline CD4 231, and current CD4 231 raise risk, pushing the score above threshold. All three align. These are the top three among many features used by the model.","231","24\/11\/2025","Valid","Routine","24\/05\/2025","No","16\/07\/2016","2","0.009693","-0.01343","0.00257","0.013798","-0.00536","0.020197","0.122078367","0.002549","0.00025","0.003609","0.003195","-0.0007","0.001276","-0.02363","-0.00186","-0.00448","0.007588","0.000111","0.000992","0.001704","0.050003","1.54E-06","0.004839","-0.00118","0.001012","0.008281","0.00996","0.299334352","probability","1","0.49","time_since_diagnosis_at_scheduled_appointment","Baseline CD4 result","CD4_Count","4375","231","231","increases","increases","increases","0","0","0","2","3","4","17"],["","1666702290","12\/12\/1989","67","163","123\/83","36","F","07\/20\/2015","07\/22\/2015","08\/10\/2015","423","First line","1","40","15\/02\/2016","Treatment completed","Not Established","22\/11\/2025","02\/21\/2026","NONE","11\/22\/2025","0","0","0","1","0","3","0","0","0","0","1","100","3778","36","31-45","1","Low","0.44","0","on time","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The Patient is stable and suppressed; consider 3\u00e2\u20ac\u201c6 month MMD and annual VL, plus reproductive planning\/cervical screening and BMI lifestyle counseling; otherwise continue current regimen.","What general considerations should be taken into account for ART treatment in this patient?","The Patient is virologically suppressed; continue first-line, reinforce adherence with annual VL checks, monitor toxicities, discuss pregnancy plans\/contraception and comorbidities, and consider multi\u00e2\u20ac\u2018month dispensing.","What factors suggest a need to adjust the patient\u00e2\u20ac\u2122s ART regimen?","The Patient has no current need to adjust ART\u00e2\u20ac\u201dVL 40 (suppressed), WHO stage 1, stable clinically, no TB\/NCDs, and no adherence issues or missed visits.","The model predicted no action mainly because 10.3 years post-diagnosis raises risk; In our cohort, counterintuitively, baseline\/current CD4 (423) aligned with higher risk; score stayed below follow-up threshold. These are the top three among many features used by the model.","423","22\/11\/2025","Valid","Routine","03\/02\/2025","No","06\/08\/2016","2","0.004947","0.028889","-0.01091","0.017285","0.000683","0.018899","0.093827","0.001659","0.000122","-0.00386","0.002539","0.007132","0.000596","-0.02263","-0.00253","-0.00237","0.008567","-0.0075","-0.00563","-0.00037","-0.00283","1.51E-06","0.002689","-0.0029","-0.00024","0.00572","0.008211","0.299334352","probability","1","0.56","time_since_diagnosis_at_scheduled_appointment","Baseline CD4 result","CD4_Count","3778","423","423","increases","increases","increases","0","0","0","2","3","4","16"],["","1666702463","13\/07\/1985","54","166","99\/66","40","M","04\/07\/2016","04\/07\/2016","05\/03\/2016","113","First line","1","172","07\/06\/2016","Treatment completed","Established","27\/01\/2026","02\/25\/2026","NONE","01\/26\/2026","-1","0","0","1","0","3","0","0","0","0","1","100","3582","41","31-45","1","Low","0.34","0","on time","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The Patient seems stable; low-level viremia (172) calls for adherence check and repeat VL, verify current CD4 and continue cotrimoxazole if <200; ensure ART refill.","What general considerations should be taken into account for ART treatment in this patient?","The Patient looks stable with low VL; let\u00e2\u20ac\u2122s continue DTG-based first-line, reinforce adherence, routine VL, check CD4 for CTX need, review labs\/interactions, optimize differentiated care.","What factors suggest a need to adjust the patient\u00e2\u20ac\u2122s ART regimen?","The Patient has low-level viremia (172), is clinically stable, and no toxicity\u00e2\u20ac\u201dso no current need to change ART; just reinforce adherence and repeat VL.","The model predicted no action mainly because time since diagnosis 9.8 years, viral load 172, and height 166 cm raise risk; score stayed below follow-up threshold. All align. These are the top three among many features used by the model.","113","26\/01\/2026","Valid","Routine","28\/10\/2025","No","07\/12\/2016","0","0.005136","-0.0653","-0.00143","-0.00282","-0.00226","0.015398","0.119882497","0.002403","0.000431","0.003386","0.001894","0.001573","9.71E-05","-0.038","0.004619","0.004638","0.001915","-0.00068","-0.00228","0.000189","-0.00231","4.36E-06","0.002092","-0.01746","-0.00232","0.006408","0.007565","0.299334352","probability","1","0.66","time_since_diagnosis_at_scheduled_appointment","Viral_Load","height","3582","172","166","increases","increases","increases","0","0","0","2","1","5","17"],["","1666702681","15\/01\/1992","77","170","103\/77","34","F","05\/16\/2017","05\/16\/2017","05\/16\/2017","506","First line","1","36","29\/06\/2020","Treatment completed","Established","24\/11\/2025","02\/23\/2026","NONE","11\/24\/2025","0","0","0","1","0","3","0","0","0","0","1","100","3114","34","31-45","1","Low","0.46","0","on time","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The Patient remains stable and virally suppressed; continue first-line, schedule annual VL, consider longer refill intervals, address overweight with lifestyle counseling, and ensure contraception\/cervical screening.","What general considerations should be taken into account for ART treatment in this patient?","The Patient is stable and virally suppressed on first-line\u00e2\u20ac\u201dlet\u00e2\u20ac\u2122s continue, reinforce adherence, schedule VL monitoring, review contraception\/pregnancy plans, consider MMD, and keep up NCD\/cervical screening.","What factors suggest a need to adjust the patient\u00e2\u20ac\u2122s ART regimen?","The Patient is stable and suppressed; no adjustment needed now\u00e2\u20ac\u201donly if toxicity, drug interactions, pregnancy intentions, adherence problems, or a rising viral load occur.","The model predicted no action mainly because time since diagnosis (~8.5 years) raises risk; in our cohort, counterintuitively, baseline CD4 (506) and CD4 count (506) aligned with higher risk. The overall score stayed below the follow-up threshold. These are the top three among many features used by the model.","506","24\/11\/2025","Valid","Routine","21\/05\/2025","No","30\/01\/2018","2","-0.0033","0.070122","-0.00165","0.001664","0.011618","0.016217","0.100124741","0.002","0.000487","0.00282","-0.00124","0.005787","0.002346","-0.01864","0.000795","-0.00014","0.005863","-0.00863","-0.00856","-0.00063","-0.00255","9.62E-07","-0.00353","-0.02245","-0.00057","0.007083","0.008414","0.299334352","probability","1","0.54","time_since_diagnosis_at_scheduled_appointment","Baseline CD4 result","CD4_Count","3114","506","506","increases","increases","increases","0","0","0","2","3","4","17"],["","1835202017","15\/02\/1975","46.5","150","129\/77","50","F","05\/07\/2005","04\/21\/2015","04\/21\/2015","101","First line","1","558","14\/01\/2017","Treatment completed","Not Established","24\/01\/2026","02\/21\/2026","Hypertension","01\/24\/2026","0","0","0","1","0","3","0","0","0","0","1","100","7567","51","46-60","1","Low","0.27","0","on time","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The Patient has invalid VL and CD4 101; I'd repeat VL, reinforce adherence, ensure TMP\u00e2\u20ac\u2018SMX, consider CrAg\/TB screening, and ensure antihypertensives don\u00e2\u20ac\u2122t clash with ART.","The patient has both HIV and Hypertension. How might this affect ART treatment or what considerations are important in managing this patient?","The Patient has hypertension; tailor ART around BP meds\u00e2\u20ac\u201dprefer DTG, avoid abacavir if CV risk; monitor kidneys with TDF+ACEI\/ARB; repeat invalid VL.","What factors suggest a need to adjust the patient\u00e2\u20ac\u2122s ART regimen?","The Patient has CD4 101 and VL 558 (invalid); if repeat confirms viremia, long-term first-line use suggests resistance, so consider switching.","The model predicted no action mainly because diagnosed ~20.7 years ago, viral load 558, and CD4 190 each increases risk; yet below the follow-up threshold; all three align. These are the top three among many features used by the model.","190","24\/01\/2026","Invalid","Routine","25\/10\/2025","No","21\/01\/2017","0","0.004179","-0.06899","-0.00529","-0.00518","-0.02947","0.008217","0.093481","0.000531","0.000586","0.00113","0.000238","0.005464","0.003349","-0.02826","-0.00405","-0.0012","0.000725","-0.00163","0.004459","0.001104","-0.00374","4.98E-07","-0.0047","-0.0081","-0.001","0.005344","0.005674","0.299334352","probability","1","0.73","time_since_diagnosis_at_scheduled_appointment","Viral_Load","Baseline CD4 result","7567","558","190","increases","increases","increases","0","0","0","2","1","3","16"],["","1544002247","22\/12\/2007","61","161","115\/60","18","M","7\/22\/2014","7\/22\/2014","2\/6\/2016","211","First line","1","74","11\/16\/2019","Treatment completed","Not Established","18\/12\/2025","3\/21\/2026","","12\/18\/2025","0","0","0","1","0","3","0","0","0","0","1","100","4167","18","<18","1","Low","0.53","1","Unknown","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The patient needs continual monitoring of CD4 counts and viral load considering their age, HIV stage 1 status, and completed TB treatment.","What should be considered for ART treatment when no NCDs are recorded for this patient?","The patient, with no NCDs recorded, has a current CD4 count of 211 and a manageable viral load. Keep this in mind for optimal ART treatment.","What factors suggest a need to adjust the patient\u2019s ART regimen?","The patient's low CD4 count and a high viral load could indicate a need to adjust the current ART regimen.","The model predicted follow-up mainly because time since diagnosis (~11.4 years), a baseline CD4 result of 817, and a current CD4 count of 211 all raise risk. Together, they pushed the score above the threshold indicating follow-up. All three drivers point the same way. These are the top three among many features used by the model.","817","2025-12-18","Valid","Routine","2025-09-20","No","2019-11-16","3","0.003676799485","-0.01785517815","0.004290022805","0.01436208658","0.008407806142","0.01644399406","0.1110272117","0.002096742535","0.0007306112885","0.0007253236903","0.003712389818","-0.006235611694","0.001055972439","-0.01869236771","0.006446783894","0.01200422207","0.00777928503","0.006780476634","0.000534390283","1.13E-05","0.04217032651","5.14E-06","0.002134162172","0.005387051555","0.001211366824","0.008999301488","0.00992478775","0.2993343519","probability","1","0.47","time_since_diagnosis_at_scheduled_appointment","Baseline CD4 result","CD4_Count","4167","817","211","increases","increases","increases","0","0","0","2","3","4","16"],["","1666701967","07\/11\/1981","57","154","113\/73","44","F","3\/28\/2014","3\/28\/2014","4\/25\/2014","256","First line","1","20","8\/3\/2019","Treatment completed","Established","17\/12\/2025","3\/23\/2026","","12\/22\/2025","5","0","0","0","1","3","25","0","0","0","0","75","4282","44","31-45","1","Medium","0.32","0","Unknown","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The patient has successfully completed TB treatment, maintains a healthy CD4 count, and is on a first line regimen, yet has a tendency for late arrivals.","What should be considered for ART treatment when no NCDs are recorded for this patient?","The patient has a stable clinical status with controlled HIV. You may continue the first-line ART regimen and closely monitor their response and adherence.","What factors suggest a need to adjust the patient\u2019s ART regimen?","The patient's ART regimen might require adjustment considering the consistently low CD4 count and the invalid last viral load test result. However, other clinical indicators are stable.","The model predicted no action mainly because, although time since diagnosis (~12 years), a baseline CD4 result of 256, and a current CD4 count of 256 all raise risk, the combined impact did not exceed the threshold for follow-up. These are the top three among many features used by the model.","256","2025-12-22","Invalid","Routine","2024-06-15","No","2019-08-03","3","0.01257020122","-0.01879622162","0.003668062747","0.0003872929205","-0.001112976031","-0.03735708199","0.06535330423","0.005542033083","0.001294774784","-0.003871224368","-1.36E-06","0.004593650084","0.0003809882711","-0.02389035879","-0.001085791138","-0.001543111218","0.006842180962","-0.0002331425829","-0.004449002509","9.85E-05","-0.003012953058","1.86E-06","-0.0002081380857","-0.001879267055","0.002788879711","0.007592039808","0.006939172952","0.2993343519","probability","1","0.68","time_since_diagnosis_at_scheduled_appointment","Baseline CD4 result","CD4_Count","4282","256","256","increases","increases","increases","0","0","0","2","3","4","17"],["","1666701994","29\/12\/1990","87","161","127\/80","35","F","5\/6\/2014","5\/6\/2014","5\/6\/2014","303","First line","1","15845","12\/10\/2018","Treatment completed","Not Established","13\/10\/2025","3\/19\/2026","","2\/18\/2026","0","0","0","1","0","1","0","0","0","0","1","100","4178","35","31-45","1","Low","0.37","0","Unknown","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The patient has completed TB treatment successfully, but considering the first line regimen and viral load, further HIV management might be required.","What should be considered for ART treatment when no NCDs are recorded for this patient?","The patient is on first-line ART regimen without any NCDs. It's essential to monitor for side effects, adherence, and changes in their CD4 count and viral load.","What factors suggest a need to adjust the patient\u2019s ART regimen?","The patient's relatively high viral load of 15845, despite being on the first-line ART for many years, suggests a potential need for regimen adjustment.","The model predicted no action mainly because, despite the fact that viral load (15845), time since diagnosis (around 12 years), and baseline CD4 result (303) each raise risk, their collective impact kept the score below the follow-up threshold. These are the top three among many features used by the model.","303","2025-10-13","Valid","Routine","2025-10-13","No","2018-12-10","3","0.004152227411","-0.002054166776","-0.02536351558","-0.004386452713","0.03312056878","0.01719888747","0.07960003841","0.001557184591","0.0004845076654","0.002871586741","0.0003655024085","-0.003213135874","0.0005908182328","-0.01720416884","-0.0005440609053","-0.001038253391","0.008166564534","0.002890832429","-0.002720939211","-0.0009162505877","-0.002579312895","1.29E-06","-0.006124906012","-0.02025471647","-0.001718052367","0.004154396504","0.004184120959","0.2993343519","probability","1","0.63","Viral_Load","time_since_diagnosis_at_scheduled_appointment","Baseline CD4 result","15845","4178","303","increases","increases","increases","0","0","0","1","2","3","16"],["","1666702063","19\/10\/1975","62","164.5","128\/70","50","F","8\/13\/2014","8\/13\/2014","9\/24\/2014","300","First line","1","37","1\/23\/2019","Treatment completed","Established","16\/12\/2025","3\/19\/2026","Asthma","12\/16\/2025","0","0","0","1","0","3","0","0","0","0","1","100","4143","50","46-60","1","Low","0.49","0","Unknown","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The patient, with HIV and Asthma, has been maintaining well on ART, but ensuring consistent treatment adherence and monitoring viral loads will be essential.","What general considerations should be taken into account for ART treatment in this patient?","The patient, a 50-year-old female, is on a first-line ART treatment. She also has Asthma, so make sure there's no interaction between her treatments.","What factors suggest a need to adjust the patient\u2019s ART regimen?","The patient's consistently low viral load and regular attendance to appointments suggest no immediate need to adjust the existing ART regimen.","\"The model predicted no action mainly because time since diagnosis (about 11.3 years), baseline CD4 result (300), and a CD4 count of 300 each raise risk. However, their combined impact did not exceed the follow-up threshold. These are the top three among many features used by the model.\"","300","2025-12-16","Invalid","Routine","2024-06-18","No","2019-01-23","3","0.006866782297","-0.003721263512","0.008564420203","0.01263340321","0.007062822119","0.02118183406","0.1103329072","0.002254273902","0.000467600546","0.002958552407","0.001359075352","0.004442548524","0.0003183290847","-0.02113412399","-0.0008695929281","-0.0008856044965","0.01335492154","0.002462923469","0.01604024721","1.60E-05","-0.001861137573","2.75E-06","-0.002366171997","-0.009064035155","0.0001559794469","0.01041396709","0.01055695951","0.2993343519","probability","1","0.51","time_since_diagnosis_at_scheduled_appointment","Baseline CD4 result","CD4_Count","4143","300","300","increases","increases","increases","0","0","0","2","3","4","16"],["","1666702104","05\/02\/1978","65","157","111\/76","48","F","10\/16\/2014","10\/31\/2014","12\/10\/2014","231","First line","1","68244","2\/16\/2016","Treatment completed","Established","17\/12\/2025","3\/19\/2026","","2\/18\/2026","-1","0","0","1","0","1","0","0","0","0","1","100","4080","48","46-60","1","Low","0.42","0","Unknown","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The patient, currently in WHO HIV Stage 1, shows valid viral load indicating routine monitoring. Despite being active in TB, they successfully completed the treatment.","What should be considered for ART treatment when no NCDs are recorded for this patient?","The patient's regimen should continue as they show no NCDs. Monitor their CD4 count, viral load, and any signs of opportunistic infections closely.","What factors suggest a need to adjust the patient\u2019s ART regimen?","The patient's high viral load suggests a possible need to adjust the ART regimen, indicating that the current treatment may not be fully effective.","The model predicted no action mainly because viral load (68,244), time since diagnosis (about 11.3 years), and a baseline CD4 result (231) all raise risk. Despite these factors, the overall score stayed below the follow-up threshold. All three drivers point the same way. These are the top three among many features.","231","2025-12-16","Valid","Routine","2025-09-18","No","2016-02-16","1","0.01254285948","-0.007973115081","-0.03333306499","0.005934582577","0.005413065596","0.03056854091","0.09539175564","0.001627720968","0.0002933890432","0.001370357025","0.001474224357","-0.004912269283","0.0006456110971","-0.01223136518","0.002922632898","-0.000706621244","0.009639034214","-0.002018829905","0.01557916088","0.0002844763577","-0.002720047024","8.42E-07","-0.00654137975","-0.007344774524","0.001341635071","0.005151674845","0.005967143294","0.2993343519","probability","1","0.58","Viral_Load","time_since_diagnosis_at_scheduled_appointment","Baseline CD4 result","68244","4080","231","increases","increases","increases","0","0","0","1","2","3","17"],["","1666702798","21\/11\/1974","61","172","125\/59","51","F","4\/4\/2018","4\/4\/2018","4\/4\/2018","211","First line","1","22","1\/3\/2019","Treatment completed","Established","22\/12\/2025","3\/23\/2026","","12\/22\/2025","0","0","0","1","0","3","0","0","0","0","1","75","2819","51","46-60","1","Low","0.35","0","Unknown","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The patient has responded well to first line ART, with improved CD4 count. She successfully completed TPT and is consistent with appointments. There are no reported NCDs.","What should be considered for ART treatment when no NCDs are recorded for this patient?","The patient, despite having no recorded NCDs, needs to be monitored for their adherence to the first-line ART treatment and the trend in CD4 count.","What factors suggest a need to adjust the patient\u2019s ART regimen?","The patient's increased CD4 count and completed TB treatment suggest stability, however, the invalid viral load result may indicate a need for ART adjustment.","The model predicted no action mainly because, although time since diagnosis (~7.7 years), CD4 count of 211, and height of 172 cm each raise risk, their combined effect did not push the overall score above the follow-up threshold. These are the top three among many features used by the model.","83","2025-12-22","Invalid","Routine","2024-02-14","No","2019-01-03","3","0.01360145554","-0.02957523193","0.004208565034","-0.01153946896","0.003777808305","-0.03738117702","0.09089597014","0.004712839109","0.00083912007","0.001080378887","0.000564176227","0.002059789765","0.0006863083466","-0.02300729558","-0.002164690717","-0.001337774215","0.005691318285","0.004791034159","0.01347251322","-0.0002811568152","-0.002997996385","1.71E-06","0.001743784901","0.0006716951384","-0.0009815083934","0.006281744695","0.006886721152","0.2993343519","probability","1","0.65","time_since_diagnosis_at_scheduled_appointment","CD4_Count","height","2819","211","172","increases","increases","increases","0","0","0","2","4","5","16"],["","1666703303","30\/10\/1993","93","174.3","139\/99","32","F","4\/17\/2023","4\/17\/2023","4\/24\/2023","373","First line","1","55","6\/16\/2023","Discontinued","Established","14\/10\/2025","3\/23\/2026","","2\/23\/2026","1","0","0","1","0","2","25","0","0","1","1","75","911","32","31-45","1","Medium","0.38","0","Unknown","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The patient is currently stable with controlled viral load and first line ART treatment. However, her late appointment arrivals could impact regimen efficacy.","What should be considered for ART treatment when no NCDs are recorded for this patient?","The patient has a valid viral load and has started ART. Consider adherence to ART, CD4 count, and viral suppression for her ART treatment, despite no recorded NCDs.","What factors suggest a need to adjust the patient\u2019s ART regimen?","The patient's consistent late arrivals, coupled with a stable but not ideal viral load, hint at a possible need to tweak their ART regimen.","The model predicted no action mainly because time since diagnosis (~2.8 years), along with CD4 count (373) and baseline CD4 result (373), all raise risk. However, their combined effect did not push the score above the follow-up threshold. These are the top three among many features used by the model.","373","2025-10-15","Valid","Routine","2025-04-16","No","2023-06-16","3","0.005648127421","0.009502309122","0.0005048952025","-0.002399951813","0.05940365157","-0.03574181706","0.03753046355","0.00430302156","0.001471467438","0.002344204314","-0.002343344651","0.01045761525","0.0002718085597","-0.02361244817","-0.001387932297","-0.0001484715895","0.004047490312","-0.001525541802","-0.003537271655","-0.0002974965848","-0.00243447914","1.97E-07","-0.003150306801","0.001723030519","0.003176413051","0.006688519531","0.00930667303","0.2993343519","probability","1","0.62","time_since_diagnosis_at_scheduled_appointment","Baseline CD4 result","CD4_Count","911","373","373","increases","increases","increases","0","0","0","2","3","4","19"],["","1666703365","15\/04\/2002","58","172.5","111\/69","23","M","2\/23\/2024","2\/23\/2024","2\/23\/2024","199","First line","1","40","2\/23\/2024","Treatment completed","Not Established","15\/12\/2025","3\/23\/2026","","12\/15\/2025","0","0","0","1","0","3","25","0","0","0","1","75","661","24","18-30","1","Medium","0.3","0","Unknown","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The Patient, currently on the first line of ART, has a low CD4 count and stable viral load, necessitating a focus on immune system strengthening.","What should be considered for ART treatment when no NCDs are recorded for this patient?","The patient is responding well to the first line ART, with improved CD4 and controlled viral load. Current regimen continuation seems appropriate, considering no NCDs recorded.","What factors suggest a need to adjust the patient\u2019s ART regimen?","The patient's stable CD4 count and low viral load indicate no immediate need to adjust the current ART regimen.","The model predicted no action mainly because time since diagnosis (~1.8 years), CD4 count of 199, and height of 172.5 cm all raise risk. Despite this, the combined effects stayed below the follow-up threshold. These are the top three among many features used by the model.","135","2025-12-15","Valid","Routine","2025-02-15","No","2024-02-23","3","0.01325883076","-0.0244845524","0.001638761364","-0.001043804501","0.009435989873","-0.0318199029","0.0314821628","0.0050685563","0.002050525978","-0.002996421385","-0.001026101441","0.009471217907","0.001351511491","-0.03645818219","0.009551909837","0.00787836682","-0.002273832317","0.002221332748","-0.0002599564107","-0.000641545726","-0.001710828874","1.43E-07","-0.0004089599939","0.0006251021012","-0.0006367801204","0.005777361764","0.006511240531","0.2993343519","probability","1","0.7","time_since_diagnosis_at_scheduled_appointment","CD4_Count","height","661","199","172.5","increases","increases","increases","0","0","0","2","4","5","16"],["","1666703469","04\/03\/2005","50","172","114\/73","21","M","2\/3\/2025","2\/3\/2025","2\/3\/2025","82","First line","1","38","3\/22\/2025","Treatment completed","Established","4\/10\/2025","3\/23\/2026","","2\/23\/2026","0","0","0","1","0","2","25","0","0","1","1","75","243","21","18-30","1","Medium","0.11","0","Unknown","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The patient, on first line regimen and with a relatively low CD4 count, may need continuous monitoring and ART adherence encouragement.","What should be considered for ART treatment when no NCDs are recorded for this patient?","The patient, with no recorded NCDs, ART treatment should primarily focus on their CD4 count, WHO HIV stage, and viral load. Regular follow-ups are essential.","What factors suggest a need to adjust the patient\u2019s ART regimen?","The patient's CD4 count of 82 and the viral load of 38 might indicate a need to reevaluate the effectiveness of the present ART regimen.","The model predicted no action mainly because, although time since diagnosis (roughly 9.3 years), height (172 cm), and baseline CD4 result (82) raise risk, these factors collectively kept the overall score below the follow-up threshold. These are the top three among many features used by the model.","82","2025-10-04","Valid","Routine","2025-05-31","No","2025-03-22","3","-0.002035338837","-0.0756490427","0.004040480524","-0.005823453336","-0.01672202545","-0.02214500521","-0.03822056047","0.002170031459","0.0003344307854","0.0005989418","-0.0001880556676","0.006644825791","0.002277910065","-0.03284714572","0.0002604501571","-0.003420339815","-0.007536583023","0.0003720316526","-0.001381011545","-0.0006768986948","-0.002410142588","6.17E-08","-0.000882150693","0.001406611925","-0.0009648512055","0.002986378843","0.003985320501","0.2993343519","probability","1","0.89","time_since_diagnosis_at_scheduled_appointment","height","Baseline CD4 result","243","172","82","increases","increases","increases","0","0","0","2","5","3","18"],["","1835202017","15\/02\/1975","47","150","160\/75","51","F","5\/7\/2005","4\/21\/2015","4\/21\/2015","101","First line","1","558","1\/14\/2017","Treatment completed","Not Established","25\/10\/2025","3\/21\/2026","Hypertension","2\/21\/2026","0","0","0","1","0","1","0","0","0","0","1","100","7476","51","46-60","1","Low","0.29","0","Unknown","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The patient has hypertension and a low CD4 count, so closely monitoring her viral load and blood pressure during ART treatment is crucial.","The patient has both HIV and Hypertension. How might this affect ART treatment or what considerations are important in managing this patient?","The patient's hypertension must be well-managed to prevent adverse effects on their HIV condition and avoid complications from their ART treatment.","What factors suggest a need to adjust the patient\u2019s ART regimen?","The Patient's relatively low CD4 count of 101 along with a high viral load of 558 could signify a need to revise their ART regimen.","The model predicted no action mainly because, although time since diagnosis (~21 years), a viral load of 558, and a baseline CD4 result of 190 each raise risk, their aggregate effect kept the score below the follow-up cutoff. All three drivers point the same way. These are the top three among many features.","190","2025-10-25","Valid","Routine","2025-10-25","No","2017-01-14","3","0.001673553483","-0.06801821147","-0.004410654621","-0.003496260948","-0.01691290142","0.009655858199","0.094431294","0.001101576707","0.0005704063485","0.0004073404766","0.0001193416168","0.007365414514","0.003333842396","-0.03002928248","-0.003417245383","-0.001677365718","0.00173359792","-0.002585541254","0.006042550683","0.001317463629","-0.003165478665","5.18E-07","-0.004338196201","-0.006847991558","-0.0001670523204","0.005888652863","0.006048096021","0.2993343519","probability","1","0.71","time_since_diagnosis_at_scheduled_appointment","Viral_Load","Baseline CD4 result","7476","558","190","increases","increases","increases","0","0","0","2","1","3","17"],["0","1000000000","7\/19\/1992","70","165","129\/88","32","M","06\/12\/2018","06\/12\/2019","06\/12\/2019","603","First line","1","0","11\/04\/2019","Treatment completed","Established","3\/10\/2026","3\/18\/2026","","4\/19\/2025","0","0","1","0","0","3","0","0","0","0","1","100","2506","32.75838467","31-45","1","Low","0.520046391","0","Unknown","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The Patient is virally suppressed, WHO1; continue first-line ART, routine VL\/renal monitoring, address borderline BP\/BMI with lifestyle counseling, and reinforce adherence given elevated IIT prediction.","What should be considered for ART treatment when no NCDs are recorded for this patient?","The Patient has no recorded NCDs; continue first-line DTG-based ART, and routinely screen for hypertension\/diabetes, renal function, lipids, weight, and potential drug interactions.","What factors suggest a need to adjust the patient\u2019s ART regimen?","The Patient is stable with suppressed VL; continue current first-line, consider 6-month dispensing, and maintain routine NCD screening\u2014BP, glucose, renal\u2014diastolic is borderline.","The model predicted follow-up mainly because long time since diagnosis ~6.9 years, CD4 count 603, and being on ART increase risk. In our cohort, this profile often appeared before missed or late appointments.","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""],["0","1000000001","7\/19\/1992","70","165","129\/88","32","M","06\/12\/2018","06\/12\/2019","06\/12\/2019","603","First line","1","0","11\/04\/2019","Treatment completed","Established","3\/10\/2026","3\/19\/2026","","4\/19\/2025","0","0","1","0","0","3","0","0","0","0","1","100","2506","32.75838467","31-45","1","Low","0.520046391","0","Unknown","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The Patient is virally suppressed, WHO1; continue first-line ART, routine VL\/renal monitoring, address borderline BP\/BMI with lifestyle counseling, and reinforce adherence given elevated IIT prediction.","What should be considered for ART treatment when no NCDs are recorded for this patient?","The Patient has no recorded NCDs; continue first-line DTG-based ART, and routinely screen for hypertension\/diabetes, renal function, lipids, weight, and potential drug interactions.","What factors suggest a need to adjust the patient\u2019s ART regimen?","The Patient is stable with suppressed VL; continue current first-line, consider 6-month dispensing, and maintain routine NCD screening\u2014BP, glucose, renal\u2014diastolic is borderline.","The model predicted follow-up mainly because long time since diagnosis ~6.9 years, CD4 count 603, and being on ART increase risk. In our cohort, this profile often appeared before missed or late appointments.","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""],["0","1000000002","7\/19\/1992","70","165","129\/88","32","M","06\/12\/2018","06\/12\/2019","06\/12\/2019","603","First line","1","0","11\/04\/2019","Treatment completed","Established","3\/10\/2026","3\/17\/2026","","4\/19\/2025","0","0","1","0","0","3","0","0","0","0","1","100","2506","32.75838467","31-45","1","Low","0.520046391","0","Unknown","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The Patient is virally suppressed, WHO1; continue first-line ART, routine VL\/renal monitoring, address borderline BP\/BMI with lifestyle counseling, and reinforce adherence given elevated IIT prediction.","What should be considered for ART treatment when no NCDs are recorded for this patient?","The Patient has no recorded NCDs; continue first-line DTG-based ART, and routinely screen for hypertension\/diabetes, renal function, lipids, weight, and potential drug interactions.","What factors suggest a need to adjust the patient\u2019s ART regimen?","The Patient is stable with suppressed VL; continue current first-line, consider 6-month dispensing, and maintain routine NCD screening\u2014BP, glucose, renal\u2014diastolic is borderline.","The model predicted follow-up mainly because long time since diagnosis ~6.9 years, CD4 count 603, and being on ART increase risk. In our cohort, this profile often appeared before missed or late appointments.","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""],["0","1000000003","7\/19\/1992","70","165","129\/88","32","M","06\/12\/2018","06\/12\/2019","06\/12\/2019","603","First line","1","0","11\/04\/2019","Treatment completed","Established","3\/10\/2026","3\/14\/2026","","4\/19\/2025","0","0","1","0","0","3","0","0","0","0","1","100","2506","32.75838467","31-45","1","Low","0.520046391","0","Unknown","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The Patient is virally suppressed, WHO1; continue first-line ART, routine VL\/renal monitoring, address borderline BP\/BMI with lifestyle counseling, and reinforce adherence given elevated IIT prediction.","What should be considered for ART treatment when no NCDs are recorded for this patient?","The Patient has no recorded NCDs; continue first-line DTG-based ART, and routinely screen for hypertension\/diabetes, renal function, lipids, weight, and potential drug interactions.","What factors suggest a need to adjust the patient\u2019s ART regimen?","The Patient is stable with suppressed VL; continue current first-line, consider 6-month dispensing, and maintain routine NCD screening\u2014BP, glucose, renal\u2014diastolic is borderline.","The model predicted follow-up mainly because long time since diagnosis ~6.9 years, CD4 count 603, and being on ART increase risk. In our cohort, this profile often appeared before missed or late appointments.","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""],["0","1000000004","7\/19\/1992","70","165","129\/88","32","M","06\/12\/2018","06\/12\/2019","06\/12\/2019","603","First line","1","0","11\/04\/2019","Treatment completed","Established","3\/10\/2026","3\/7\/2026","","4\/19\/2025","0","0","1","0","0","3","0","0","0","0","1","100","2506","32.75838467","31-45","1","Low","0.520046391","1","Unknown","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The Patient is virally suppressed, WHO1; continue first-line ART, routine VL\/renal monitoring, address borderline BP\/BMI with lifestyle counseling, and reinforce adherence given elevated IIT prediction.","What should be considered for ART treatment when no NCDs are recorded for this patient?","The Patient has no recorded NCDs; continue first-line DTG-based ART, and routinely screen for hypertension\/diabetes, renal function, lipids, weight, and potential drug interactions.","What factors suggest a need to adjust the patient\u2019s ART regimen?","The Patient is stable with suppressed VL; continue current first-line, consider 6-month dispensing, and maintain routine NCD screening\u2014BP, glucose, renal\u2014diastolic is borderline.","The model predicted follow-up mainly because long time since diagnosis ~6.9 years, CD4 count 603, and being on ART increase risk. In our cohort, this profile often appeared before missed or late appointments.","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""],["0","1000000005","7\/19\/1992","70","165","129\/88","32","M","06\/12\/2018","06\/12\/2019","06\/12\/2019","603","First line","1","0","11\/04\/2019","Treatment completed","Established","3\/10\/2026","2\/15\/2026","","4\/19\/2025","0","0","1","0","0","3","0","0","0","0","1","100","2506","32.75838467","31-45","1","Low","0.520046391","0","Unknown","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The Patient is virally suppressed, WHO1; continue first-line ART, routine VL\/renal monitoring, address borderline BP\/BMI with lifestyle counseling, and reinforce adherence given elevated IIT prediction.","What should be considered for ART treatment when no NCDs are recorded for this patient?","The Patient has no recorded NCDs; continue first-line DTG-based ART, and routinely screen for hypertension\/diabetes, renal function, lipids, weight, and potential drug interactions.","What factors suggest a need to adjust the patient\u2019s ART regimen?","The Patient is stable with suppressed VL; continue current first-line, consider 6-month dispensing, and maintain routine NCD screening\u2014BP, glucose, renal\u2014diastolic is borderline.","The model predicted follow-up mainly because long time since diagnosis ~6.9 years, CD4 count 603, and being on ART increase risk. In our cohort, this profile often appeared before missed or late appointments.","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""],["0","1000000006","7\/19\/1992","70","165","129\/88","32","M","06\/12\/2018","06\/12\/2019","06\/12\/2019","603","First line","1","0","11\/04\/2019","Treatment completed","Established","3\/10\/2026","3\/20\/2026","","4\/19\/2025","0","0","1","0","0","3","0","0","0","0","1","100","2506","32.75838467","31-45","1","Low","0.520046391","1","Unknown","Based on the data, specify any treatment considerations or factors that should be taken into account for managing the patient at this stage","The Patient is virally suppressed, WHO1; continue first-line ART, routine VL\/renal monitoring, address borderline BP\/BMI with lifestyle counseling, and reinforce adherence given elevated IIT prediction.","What should be considered for ART treatment when no NCDs are recorded for this patient?","The Patient has no recorded NCDs; continue first-line DTG-based ART, and routinely screen for hypertension\/diabetes, renal function, lipids, weight, and potential drug interactions.","What factors suggest a need to adjust the patient\u2019s ART regimen?","The Patient is stable with suppressed VL; continue current first-line, consider 6-month dispensing, and maintain routine NCD screening\u2014BP, glucose, renal\u2014diastolic is borderline.","The model predicted follow-up mainly because long time since diagnosis ~6.9 years, CD4 count 603, and being on ART increase risk. In our cohort, this profile often appeared before missed or late appointments.","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""]]}